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Articular cartilage is a highly specialized, hierarchically organized tissue covering the articular 
surfaces of diarthrodial joints that absorbs and distributes forces upon mechanical loading and 
enables low-friction movement between opposing bone ends. Despite a strong resilience towards 
mechanical stress, once damaged cartilage is generally not regenerated due to a limited repair 
potential of the residing cells (chondrocytes) and the local absence of vascularized blood vessels 
and nerves. Eventually, this may lead to osteoarthritis, a chronic degenerative disorder of the 
synovial joints which has a strongly growing prevalence worldwide. Modern regenerative therapies 
that aim to rebuild cartilage tissue in vivo and in vitro using chondrocyte- and stem cell-based 
methods are still not able to produce tissue constructs with desired biomechanical properties and 
organization for long-term repair. Therefore, cartilage tissue engineering seeks for new ways to 
solve these problems. In this regard, the application of hydrogel-based scaffolding materials as 
artificial matrix environments to support the chondrogenesis of embedded cells and the 
implementation of appropriate biofabrication techniques that help to reconstitute the zonal 
structure of articular cartilage are considered as promising strategies for sophisticated cartilage 
regeneration approaches. 
In this thesis, a modular starPEG-heparin hydrogel platform as cell-instructive hydrogel scaffold 
was used in combination with a custom-designed 3D inkjet bioprinting method with the intention 
to develop a printable 3D in vitro culture system that promotes the chondrogenic differentiation of 
human mesenchymal stromal cells (hMSC) in printed cell-laden hydrogels with layered 
architectures in order to fabricate cartilage-like tissue constructs with hierarchical organization.  
Firstly, the successful bioprinting of horizontally and vertically structured, cell-free and -laden 
hydrogel scaffolds that exhibit layer thicknesses in the range of the superficial zone, the thinnest 
articular cartilage layer is demonstrated. The long-term integrity of the printed constructs and the 
cellular functionality of the plotted cells that generally had a high viability after the printing process 
are shown by a successful PDGF-BB-mediated hMSC migration assay in a printed multilayered 
hydrogel construct over a culture period of 4 weeks.  
Secondly, when the established printing procedures were applied for the chondrogenic 
differentiation of hMSCs, it was found that the printed cell-laden constructs showed a limited 
potential for in vitro chondrogenesis as indicated by a weaker immunostaining for cartilage-specific 
markers compared to casted hydrogel controls. In order to increase the post-printing cell density 
to tackle the limited printable cell concentration which was regarded as the primary reason for the 
impaired performance of the printed scaffolds, different conditions with varying culture medium 
and hydrogel compositions were tested to stimulate 3D cell proliferation. However, a significant 
3D cell number increase could not be achieved which ultimately resulted in shifting the further 




Thirdly, the chondrogenic differentiation of hMSCs in casted hydrogels proved to be successful 
which was indicated by a uniform deposition of cartilage-specific ECM molecules comparable with 
the outcomes of scaffold-free MSC micromass cultures used as reference system. However, the 
quantitative analysis of biochemical and physical properties of the engineered hydrogel constructs 
yielded still significant lower values in relation to native articular cartilage tissue. 
Fourthly, in order to improve these properties and to enhance the chondrogenesis in starPEG-
heparin hydrogels, a dualistic strategy was followed. In the first part, specific externally supplied 
stimulatory cues including a triple growth factor supply strategy and macromolecular crowding 
were applied. As second part, intrinsic properties of the modular hydrogel system such as the 
crosslinking degree, the enzymatic degradability and the heparin content were systematically and 
independently altered. It was found that while the external cues showed no supportive benefits for 
the chondrogenic differentiation, the reduction of the heparin content in the hydrogel proved to 
be a key trigger that resulted in a significantly increased cartilage-like ECM deposition and gel 
stiffness of engineered constructs with low and no heparin content. 
In conclusion, this work yielded important experiences with regards to the application of inkjet 
bioprinting for hMSC-based cartilage tissue engineering approaches. Furthermore, the obtained 
data provided valuable insights into the interaction of MSCs and a surrounding hydrogel-based 
microenvironment that can be used for the further development of chondrosupportive scaffolding 
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In a wealthy society with an increasing share of older people having an extending longevity 
combined with the so-called diseases of affluence like diabetes and obesity, age- and lifestyle-related 
medical conditions and disabilities have a growing impact on the quality of life of the affected 
people and are considered as high-risk factors for the general socioeconomic development with 
significant burdens on the healthcare systems.[1,2] Hence, tremendous efforts and resources are 
channeled into the understanding and curing of these pathologies where important progresses were 
already achieved with the application of a variety of methodologies of regenerative medicine and 
pharmaceutical drug administrations.[3]  
Among these  medical conditions, osteoarthritis (OA) being a degenerative disease of the articular 
cartilage and the surrounding joint tissue is the fastest growing joint disorder with a prevalence of 
hundreds of millions of mainly older (age 50+) people worldwide.[4] Since age and overweight are 
the major risk factors, OA is expected to be the main cause for disabilities by 2030.[5] Due to the 
intrinsically low repair potential of the affected articular cartilage, medical interventions are 
necessary. However, current clinical therapies including oral pain medications and direct joint 
injections of anti-inflammatory agents or hyaluronic acid often target only the superficial symptoms 
resulting in short-term pain relief while repair-intended surgical treatments like microfracture, 
osteochondral autografting and autologous chondrocyte transplantation (ACI) do not yet manage 
to reestablish a fully biofunctional cartilage tissue at the lesion site for the long-term use.[6] Two 
main reasons can be identified for this lack of success to effectively treat damages at the articular 
surface. Firstly, despite extensive research efforts over the last decades there is still an inadequate 
understanding of the pathological mechanisms of the initiation and the progression of OA which 
hinders the development of sophisticated biopharmaceutical therapies to tackle the onset of self-
perpetuating catabolic cycles, particularly in the important early phase of OA.[7] Secondly, it is still 
not possible to fabricate cartilage-like implants with appropriate biomechanical properties to 
replace the damaged tissue in the late stage OA where total joint replacements often remain the 




Therefore, tissue engineering and biofabrication techniques have been increasingly used in applied 
basic and clinical research to develop and discover new ways to create artificial tissue constructs 
via in vitro and in vivo chondrogenesis using chondrocyte- and stem cell-based methods for long-
term cartilage repair.[9,10] Among the large range of various approaches, 3D bioprinting of cell-laden 
hydrogel scaffolds with specifically designed bioinks is considered as highly promising for the 
reconstitution of the naturally occurring zonal architecture in engineered cartilage which is viewed 
as an important characteristic for a biomimetic tissue recreation.[11] In regard to the associated 
development of suitable biomaterials as cell-instructive scaffolding materials to direct and control 
the cellular neogenesis of cartilaginous extracellular matrix (ECM), there is a growing trend in the 
application of sulfate-containing hydrogel building blocks composed of artificially sulfated proteins 
and polysaccharides as well as naturally sulfated glycosaminoglycans (GAGs) in mainly 
chondrocyte-based approaches observable in the recent years.[12–16] This strategy is generally based 
on the rational to provide the cells with a microenvironment that mimics the composition of the 
native cartilage ECM which is enriched in sulfated proteoglycans and to bind and stabilize 
important biochemical mediators for the chondrocyte-controlled matrix synthesis and homeostasis 
as well as the chondrogenic differentiation of suitable stem cells. So far, sulfated GAG-containing 
scaffolding materials for stem cell-based chondrogenesis and their combined application with 3D 




The aim of this work was to investigate how to engineer heparin-based hydrogels in order to 
promote the chondrogenesis of embedded human bone marrow-derived mesenchymal stromal 
cells (hMSC). The applied hydrogel platform was composed of maleimide-functionalized heparin 
as the highly sulfated, bioactive GAG unit which was crosslinked with thiolated 4-arm 
poly(ethylene glycol) polymers (starPEG). The hydrogel was further modified with enzymatically 
cleavable peptide linkers and cell adhesion-mediating peptide motifs as well as preloaded with 
soluble signaling molecules to tune the biochemical and physical properties in order to develop a 
biomimetic microenvironment for a sophisticated in vitro cartilage-like tissue formation. In addition, 
a custom-made dual component inkjet bioprinter was used for the fabrication of 3D printed, 
layered cell-laden hydrogel scaffolds with the intention to reproduce the hierarchical structure of 
articular cartilage. Based on these objectives, the thesis was divided into the following three parts: 
(1) Development of procedures and protocols to print structured cell-laden hydrogel 
scaffolds with high cell viability and integral functionality to be demonstrated with 




(2) Printing and casting of hMSC-laden starPEG-heparin hydrogels for in vitro 
chondrogenesis and evaluation of the hydrogel performance to promote the 
chondrogenic differentiation in relation to these different fabrication techniques 
 
(3) Application of externally deployed stimulatory cues such as growth factor cocktails 
and macromolecular crowding, and variation of intrinsic hydrogel parameters 
including gel stiffness, enzymatic degradability and heparin content to investigate 
their influence on the chondrogenic differentiation of hydrogel embedded hMSCs 
in order to identify a suitable setup yielding cartilage-like constructs with enhanced 
biochemical and mechanical properties  
 
Introductions to the hydrogel system and the mentioned inkjet bioprinting method are given at the 
end of the following “Fundamentals” and “Materials and Methods” sections to further elucidate 



















2.1 Cartilage tissue engineering 
Cartilage tissue can be classified into 3 different types: elastic, fibrous and hyaline. All types of 
cartilage are populated by the chondrocytes which are specialized cells synthesizing the 
cartilaginous ECM. This collagen rich matrix results in a resilient tissue with a stiffness in-between 
bone and muscle tissue. Elastic cartilage can be found primarily in the auricle and is populated 
by the auricular chondrocytes. Its special characteristic is the abundance of elastic fibers made of 
elastin which are interwoven with a collagen type II network providing it with a high elasticity.[4] 
Fibrocartilage is found in intervertebral discs, menisci, as well as bone- and ligament-tendon 
interfaces. It is the only cartilage type where collagen type I fibers are found representing the 
majority of the collagen network with low amounts of collagen type II.[17] Hyaline cartilage is the 
most common type of cartilage and is found on the articular surfaces of bones and joints (articular 
cartilage) and in the bronchi, larynx, nose, ribs and trachea. It is mainly composed of a collagen 
type II-based fibrillar network.[18] Due to its avascular structure, highly dense matrix and the 
quiescence of the residing chondrocytes, articular cartilage lacks an intrinsic regeneration capability 
which makes it prone to damage and degenerative diseases .[19]  
Therefore, the focus in this part of the fundamentals will be on the articular cartilage. Firstly, an 
introduction to the articular cartilage and its most important disease is given followed by an 
overview of different regenerative and bioprinting approaches for cartilage repair. Finally, an 
overview of possible future trends is provided.  
 
2.1.1 Articular cartilage - composition, structure and functional 
properties 
Composition and molecular structure 
Articular cartilage is a highly hydrated tissue with a water content of 65% to 85%. The remaining 
solid content is composed of 60-75% collagens and 20-30% proteoglycans. Chondrocytes only 
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occupy 2% of the total volume making articular cartilage a tissue with a relatively low cell 
concentration. The matrix has a glassy (hyaline) appearance due to the highly homogeneous 
collagen-based fibrillar network having a relatively low amount of fibers compared to fibrocartilage 
with its thicker and visible collagen type I fibers. The network is formed by collagen type II/IX/XI 
heterotricopolymeric fibrils in which collagen type II is the major component (>90% of the total 
collagen content). Other collagens like type III, VI, X, XIII and XIV are found in smaller quantities 
in the matrix.[20] Collagen type VI is primarily located in the pericellular matrix of the chondrocytes, 
whereas type X is only found in hypertrophic, calcified cartilage. Proteoglycans represent the 
second biggest group of relevant biopolymers in cartilage. Aggrecan being the dominant 
proteoglycan is composed of a protein core which is grafted with mainly chondroitin sulfate and 
to a minor extend keratan sulfate (KS) GAG sidechains. The domain of its N-terminus attaches 
via an interaction with link protein onto hyaluronan forming large aggrecan aggregates which are 
interwoven with the collagen network (Figure 1). Other proteoglycans include biglycan, decorin, 
epiphycan, fibromodulin, lumican and perlecan.[21] Further major non-collagenous proteins are the 
cartilage oligomeric matrix protein (COMP), cartilage matrix protein (matrilin-1), cartilage 
intermediate layer protein (CILP), fibronectin, proline- and arginine-rich end leucine-rich protein 
(PRELP) and others.[22]  
Figure 1 – Molecular structure of the cartilage matrix as a representation of the biomolecular architecture 
of the pericellular, territorial and interterritorial matrix with their main components and interactions. Image 
adapted from Lindahl.[23] 
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The chondrocytes regulate the homeostasis of the cartilage ECM. Even though they secrete and 
maintain a multitude of matrix macromolecules, the turnover rate is relatively slow (proteoglycan 
turnover rate of about 25 years, collagen half life time of up to 400 years).[24] Despite their metabolic 
activity, chondrocytes are considered as postmitotic cells. Cartilage is an avascular and aneural 
tissue and therefore, chondrocytes reside in a hypoxic environment relying on an anaerobic 
metabolism.[25] The local ECM structure around the chondrocytes can be further divided into the 
pericellular, territorial and interterritorial matrix. The pericellular matrix (PCM) encapsulates 
the chondrocytes (2 µm-wide) and forms a special microenvironment often referred to as 
“chondron”.[26] Biglycan and decorin connect collagen type VI fibrils with matrilins which operate 
as linker molecules to aggrecan and collagen type II forming a molecular complex as the major 
building unit of the pericellular matrix. It acts as a growth factor repository and is used for 
mechanical signal transduction to the cell.[27] The territorial matrix surrounds the pericellular 
matrix and is primarily made of collagen fibrils organized in a criss-cross manner to form a fibrillar 
basket protecting the chondrocyte from mechanical impact.[25] The interterritorial matrix 
represents the majority of the cartilage ECM and is the main contributor for the biomechanical 
properties of articular cartilage. Its structure in regard to fiber orientation and biopolymer 
composition varies among the different cartilage zones.[28] The cartilage homeostasis is regulated 
by a number of proteins including chondromodulin-I and II, cartilage-derived retinoic acid-
sensitive protein and matrix Gla protein as well as growth factors such as transforming growth 
factor-ß (TGF-ß), bone morphogenic proteins, insulin-like growth factors and fibroblast growth 
factors.[18,29]  
Architecture 
Articular cartilage has a hierarchical architecture which can be classified into 4 different zones: the 
superficial zone (SZ), the middle zone (MZ), the deep zone (DZ) and the calcified cartilage 
zone (Figure 2). In the superficial zone, the collagen content is the highest (75% of dry mass) 
but the proteoglycan content is at the lowest (20% of dry mass). Chondrocytes have a small and 
elongated morphology. Along with the collagen fibrils, they have a parallel orientation in relation 
to the surface. In this zone, the cells secrete the superficial zone protein, also called lubricin, which 
is responsible for the low-friction, lubricant surface properties of the superficial zone. This protein 
can also be found in the synovial fluid which is located between the articular cartilage surfaces of 
two opposing bones.[18] The middle zone represents 40-60% of the total cartilage mass. The 
chondrocytes have a round morphology and are distributed homogeneously in a random manner 
with a lower cell density compared to the superficial layer. Collagen fibers surround them in form 
of radial bundles.[30] The collagen content is about 20% lower than in the superficial zone, in 
contrast to a 50% higher aggrecan content. The deep zone represents approximately 30% of the 
cartilage mass. It is characterized by a perpendicular arrangement of the collagen fibrils compared 
to the surface. The cells are stacked in columns while having the lowest concentration of the 
different zones. The water content is as well at the lowest with 65% whereas the proteoglycan 
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content is at the highest. The tidemark indicates the transition from the deep zone to the underlying 
calcified cartilage zone. Hypertrophic chondrocytes reside in this area producing a collagen type 
X-containing mineralized ECM. This zone is relatively metabolically inactive but serves as an 
important transition zone between the deep zone and the subchondral bone as anchor of the 
collagen fibers to fixate the articular cartilage to the bone structure.[24] In contrast to a decreasing 
cell density from the superficial to the calcified zone, the size of the cells is progressively increasing 
with hypertrophic chondrocytes being the largest. The different morphology and ECM production 
of SZ, MZ and DZ chondrocytes is thought to originate from the influence of the local mechanical 
environment of these distinct zones.[31] 
Figure 2 – Hierarchical architecture of articular cartilage. Image adapted and modified from Matta et al.[32]  
Functional properties 
The main functions of articular cartilage are the provision of a shock-absorbing tissue with a low-
friction surface to minimize peak pressures on the underlying subchondral bone.[25] The biphasic 
nature of the matrix results in a viscoelastic behavior as well as creep and stress-relaxation responses 
under different levels and durations of deformation. When contact forces are applied upon joint 
loading, an increase in interstitial fluid pressure causes a flow out of the liquid creating a high 
frictional drag on the ECM. After the compressive load is released, the fluid flows back into the 
tissue. The high density of negative charges of the aggrecan aggregates and its interaction with the 
interstitial fluid lead to a high swelling pressure and therefore a significant compressive resilience 
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of the interstitial fluid, it acts as a nutrient source and is used for cartilage metabolic waste disposal 
while serving as a joint lubricant.[34] Under loading, the zonal architecture and collagen fibril 
orientation comes into play. The superficial zone provides lubrication and a high tensile and shear 
strength due to the parallel fibril orientation. The middle zone acts as a first absorber and 
transmitter of the compressive forces. The randomly oriented collagen fibrils are firstly straightened 
and then stretched under an increasing strain. The deep zone with the highest proteoglycan content 
and perpendicular-oriented fibrils exhibits the strongest resistance to compressive stress.[24,29] 
 
2.1.2 Development and chondrogenesis 
The development of articular cartilage is closely related to the embryonic bone formation. The path 
of chondrogenesis during long bone development involves 4 different steps: mesenchymal 
condensation, chondroprogenitor proliferation and differentiation, vascular invasion and 
chondrocyte hypertrophy and terminal ossification.[18] During the early embryogenesis, 
mesenchymal progenitor cells in the lateral plate mesoderm migrate into the core of an embryonic 
limb bud and condense to a closely packed cell aggregate with a high number of cell-cell contacts.[35] 
This process is called pre-cartilaginous condensation. Cellular adhesion mediated by neural 
cadherin (N-cadherin), neural cell adhesion molecule (N-CAM) and fibronectin triggers several 
signal transduction pathways which initiate the chondrogenic differentiation.[36,37] Cells outside 
the condensation site differentiate into fibroblastic cells and form the perichondrium which is a 
protective membrane of the developing cartilage at the periphery. The condensed cells start to 
proliferate and synthesize the hyaline cartilage matrix. These early-stage, actively synthesizing 
chondrocytes are called chondroblasts. The chondrogenic differentiation process is regulated by 
transcription factors including several members of the Runx and Sox family as well as growth 
factors like BMPs, FGFs, Indian hedgehog and TGF-ß.[38] The cartilage enters a growth phase 
where appositional and interstitial growth add to the width and length of the cartilaginous limb, 
respectively. During appositional growth, mesenchymal chondroprogenitor cells at the 
chondrogenic layer of the perichondrium differentiate into chondroblasts and start secreting 
cartilage matrix. Interstitial growth adds to the length by mitotic division of differentiated 
chondrocytes from within the former condensation site (center of the diaphysis) in a columnar 
manner which eventually produce cartilage matrix leading also to a higher matrix density. As the 
growth and maturation of the hyaline cartilage bone “model” continues, chondrocytes in the center 
of the diaphysis leave the cell cycle and start differentiating into hypertrophic chondrocytes. The 
synthesis of collagen type X facilitates the mineralization of the matrix and vascular invasion of 
blood vessels onsets the endochondral ossification.[39,40] The perichondrial cells at this site 
differentiate into bone-producing osteoblasts forming a periosteum, then penetrate the 
vascularized cartilage and establish a primary center of ossification. After a progressive ossification 
of the cartilage towards the epiphysis, a second center of ossification is formed by blood vessel 
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attachment to the epiphyseal cartilage which eventually develops into the subchondral bone.[41] An 
epiphyseal plate located at the transition from the diaphysis to the epiphysis is formed having a 
layered architecture which is divided into 4 distinct zones: the ossification zone of the diaphysis, 
the hypertrophic zone, the proliferative zone and the resting zone of the epiphysial cartilage below 
the second center of ossification. After a terminal ossification where most of the hyaline cartilage 
is substituted by bone material, the epiphysial plate and the articular cartilage remain the only 
cartilaginous regions of the growing bone. The formation of the tidemark after puberty to be a 
clear boundary between the calcified cartilage and the deep zone of the articular cartilage finally 
serves as a physical barrier for vascular invasion and prevents further mineralization of the articular 
cartilage.[42] However, there are debates about the origin of the articular cartilage. It is not clear if 
the adult cartilage is either a remnant of the epiphysial cartilage which simply stopped to ossify at 
the articular surface or was newly formed after a complete resorption of the epiphysial cartilage. In 
contrast, the epiphysial plate being the main region for interstitial growth is slowly ossified until 
full closure is achieved after the pubertal growth spurt.  
 
2.1.3 Osteoarthritis - the major articular cartilage disease 
Osteoarthritis (OA) is the most common degenerative joint disease. With a prevalence of several 
hundred million people worldwide and estimated 40 million only in Europe, osteoarthritis is the 
fastest growing cause of disability worldwide leading to large socioeconomic burdens.[43,44] More 
than 18% of the german population above 18 years and almost half of the people 65+ are 
affected.[45] OA effects and is influenced by the whole synovial joint including articular cartilage, 
subchondral bone and the synovium. Despite significant efforts in clinical research, the underlying 
pathological mechanisms of disease initiation and progression are still poorly understood. A 
combination and complex interaction of biological, mechanical and structural factors play a pivotal 
role in OA development. Generally, the main driver for OA progression is the disruption of the 
homeostasis of the articular cartilage being an equilibrium of anabolic and catabolic processes 
maintained by the chondrocytes towards a catabolic, degenerative pathway.  
Although there are still debates whether OA is primarily initiated in the articular cartilage or 
subchondral bone, a first visual indicator is the fibrillation of the cartilage ECM at the articular 
surface, eventually leading to the development of fissures. This is the result of several possible 
triggers including joint trauma or persistent mechanical overuse, which can also lead to local 
chondrocyte death. An initial loss of superficial aggrecan followed by damage of the collagen 
network is characteristic for early OA. As a regenerative response, the chondrocytes adjacent to 
the fissures and the fibrillating surface become proliferative and metabolically active leading to 
chondrocyte clustering and an upregulation of the synthesis of specific ECM-related molecules, 
especially aggrecan in the very early stage.[46,47] This is accompanied by a structural and 
compositional change in the pericellular matrix resulting in an altered mechanotransduction and 
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signaling from the interterritorial matrix to the cell. Consequently, the intracellular signaling 
pathways and growth factor release and activation in the pericellular matrix are affected.[48,49] The 
breakdown products of the articular surface deterioration, often referred to as wear particles, and 
further damage-associated molecular patterns (DAMPs; endogenous molecules like ECM 
components, plasma proteins, intracellular alarmins and crystals that interact with toll-like 
receptors) released by stressed, damaged or dead cells bind to chondrocyte receptors and induce 
the expression of ECM-degrading enzymes and proinflammatory cytokines.[50–53] These include 
aggrecanases like several a disintegrin and metalloproteinase with thrombospondin-like motifs 
(ADAMTS), collagenases like metallo matrixproteinases (MMPs), especially MMP-13 and 
cytokines such as different interleukins (IL) and tumor necrosis factor α (TNF-α). After being 
released into the synovial fluid, this group of different DAMPs induces synovitis and activates 
residing macrophages in the synovium which start to secrete inflammatory cytokines and 
chemokines (Figure 3). Additionally, angiogenesis and neovascularization of the synovium result 
in the release of plasma proteins, adipokines and other cytokines into the synovial fluid adding to 
the progressing inflammation.[54,55] This leads in turn to an increased release of catabolic enzymes 
(ADAMTS and MMPs) from chondrocytes which further accelerate the degradation of the 
cartilage ECM. Eventually, a vicious, self-perpetuating degenerative cycle is initiated in which the 
catabolic processes outplay the initial efforts of repair.[51]   
Figure 3 – Signaling pathways and structural changes in osteoarthritis compared to a healthy synovial joint. 
Image adapted from Glyn-Jones et al.[56] 
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In parallel, the subchondral bone plate responses with an increase in thickness by osteoblast- and 
-clast-mediated remodeling and modeling. Additionally, periosteal cells at the joint margins start to 
proliferate and differentiate into hypertrophic chondrocytes which produce fibrocartilage-capped 
bony outgrowths called osteophytes.[57] While having a lower bone density and stiffness in early 
phase OA due to a higher bone turnover rate, significant increase in stiffness of the subchondral 
bone is observed in later stages, probably as an adaptive response to a changed biomechanical 
environment. It is believed that there is a biochemical and -mechanical crosstalk between the 
articular cartilage and the underlying subchondral bone, which induces responses in one tissue 
based on changes in the other and vice versa.[52] As the disease progresses, the degradation of the 
ECM leads to cartilage erosion and overall cartilage shrinking. Tidemark duplication and 
advancement are indicators of vascular invasion into the calcified cartilage where former 
hypertrophic chondrocytes become apoptotic and DZ and MZ chondrocytes show hypertrophic 
behavior.[58,59] These mechanisms of cartilage degradation, vascularization and mineralization 
resemble the endochondral ossification during bone development. With a reduction in cartilage 
thickness and an altered composition, a higher mechanical stress is exercised onto the remaining 
cartilage and subchondral bone which in turn further accelerates the degenerative processes. When 
matrix deterioration and fissure progression finally lead to full thickness defects in the late stages 
of OA, the synovial fluid gets in contact with the bone marrow of the subchondral bone leading 
to the development of bone cysts accompanied with the appearance of bone marrow lesions.[60,61] 
Having direct contact with the vascularized bone marrow system, regenerative attempts are 
initiated by chondroprogenitor cells from the blood. However, they build up a fibrocartilaginous 
matrix having inferior biomechanical properties than the hyaline cartilage of the native articular 
cartilage. Hence, this repair approach is again just of temporary nature. Eventually, the progression 
of the degeneration leads to a state of severe pain and immobility for the patient where a joint 
replacement often remains the only option left. 
 
2.1.4 Current treatments for cartilage repair 
Due to the described incapability of native articular cartilage for intrinsic regeneration, several 
clinically applied and approved treatments were developed for cartilage repair. They can be divided 
into surgical and non-surgical methods. Common surgical methods can be classified into 
repair-stimulating procedures such as abrasion chondroplasty, Pridie drilling and microfracturing 
(microdrilling), transplantation-based methods like osteochondral allo- and autografting 
(mosaicplasty), cell-based implantation methods such as autologous chondrocyte implantation 
(ACI) and joint replacement procedures like total knee arthroplasty. Non-surgical methods 
include mainly the application of symptoms-treating drugs for pain reduction such as nonsteroidal 
anti-inflammatory agents, opioids, corticosteroids, topical agents and others and disease-modifying 
drugs like glucosamine sulfate, chondroitin sulfate and diacerein.[6] 
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Repair-stimulating procedures aim for the spontaneous self-repair of the deteriorated cartilage 
tissue having a full thickness defect by exposure of the subchondral bone marrow and induction 
of blood-clot formation at the lesion site. Endogenous bone marrow stromal cells migrate into the 
clot region and differentiate to chondrocyte-like cells. However, these cells generally produce a 
biomechanically inferior ECM made of fibrocartilage having just short-term benefits with a lack of 
long-term repair potential. Despite these drawbacks, microfracturing being an inexpensive and 
easy-to-do-method is still the most widely used regenerative approach for cartilage repair.[62–64] An 
advanced version of microfracturing called autologous matrix-induced chondrogenesis (AMIC) 
uses an additional collagen type I/III membrane sheet which is implanted after the subchondral 
bone perforation step. This is expected to stabilize the blood clot and facilitate intrinsic cartilage 
repair attempts. Due to a limited number of studies, it is not yet possible to make a clear statement 
if the AMIC is superior to the classical microfracturing.[65,66] Mosaicplasty is applied for full 
thickness defects and uses cylindrical osteochondral plugs which are harvested from low-weight 
bearing areas of the same joint and are transplanted back into the defect. The advantage of this 
treatment lies in being a one-step-procedure and having a demonstrated improved clinical outcome 
in the long-term compared to microfracturing.[67] However, there are several disadvantages which 
are the reasons for a shrinking acceptance among surgeons. Explanting seemingly undamaged 
osteochondral tissue fragments and reimplanting them into the lesion site of the same joint just 
creates other defects which can lead to donor site morbidity. Furthermore, reported issues with 
lateral plug integration, fibrocartilage formation of the transplanted cells and the general 
complicated and aggressive nature of the procedure add to the list of problems.[68–70] ACI and its 
derivate, the matrix-assisted ACI (MACI®) use autologous chondrocytes to induce cartilage repair. 
Comparable to the osteochondral autografting, the tissue sample is harvested by a relatively small 
cartilage biopsy of a low-weight bearing area. Enzymatic digestion extracts the living chondrocytes, 
which are expanded in vitro and finally injected back into the lesion site in suspension form. A 
periosteal flap is used as a cover to ensure chondrocyte retention and integration with the 
surrounding cartilage. To circumvent this need, matrix-assisted ACI was developed by using 
scaffolding materials like a collagen or hyaluronan-based matrix for cell embedding. ACI 
techniques showed mixed results concerning the short- and long-term observations and delivered 
no significant advantages compared to the other methods.[71–73] Dedifferentiation of chondrocytes 
during expansion culture leading to fibrocartilaginous matrix deposition in vivo is a common 
problem of this method.[74] Furthermore, the need of two operations and artificial lesion creation 
due to the biopsy are additional drawbacks. Despite these limitations, a recent FDA approval of an 
MACI-based therapy using a porcine collagen membrane as matrix for full thickness cartilage 
defects of the knee is a positive signal for the development of cell-based therapies.[75] 
Generally, the mentioned methods have a low success rate for elderly people who are particularly 
susceptible for OA development and cartilage damage.[76,77] This is due to the age-related loss in 
proliferative and metabolic potential of the progenitor cells and chondrocytes. Additionally, they 
fail at reestablishing a fully functional cartilage tissue with a zonal architecture and strong integrity 
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in the defect. Therefore, new cell- and material-based methods are needed. An overview of 
currently investigated approaches and strategies is given in the next section.  
 
2.1.5 Cell- and biomaterial-based approaches for articular 
cartilage regeneration 
Tissue engineering is a very promising field for the development of future cartilage repair 
applications. The main factors involved in the engineering process concern the cell type, source 
and treatment, the scaffolding material and biochemical cues. Furthermore, external stimuli 
can be applied to reach the full potential of these approaches. These factors then must be combined 
into appropriate in vitro, ex vivo and in vivo models to understand the underlying principles and 
mechanisms of chondrogenesis, cartilage development and OA progression. 
Cells 
Several different cell types from different sources are used in cartilage tissue engineering. Among 
the most widely used cells are autologous and allogeneic chondrocytes and mesenchymal stromal 
cells (MSC). In addition, chondroprogenitor cells and particularly induced pluripotent stem cells 
(iPSC) were investigated with increased frequency and interest in the recent years. 
Chondrocytes: 
As described in the former section, articular chondrocytes are usually derived by a biopsy from the 
articular cartilage and are primarily used for ACI-based methods. Since articular cartilage is a tissue 
with a relatively low cell concentration, the small-portioned biopsies deliver usually an insufficient 
quantity of cells and therefore an expansion culture is necessary. To counterbalance the mentioned 
issues of dedifferentiation and instability of the phenotype in 2D expansion culture, 3D cell culture 
methods were developed in which the cells are expanded and differentiated on a microcarrier or 
hydrogel as 3D microenvironment.[78,79] Despite adopted protocols and growth factor 
supplementation strategies, phenotype stability remains difficult to be achieved. Allogeneic cells 
can be used in case there is potential negative influence of adjacent inflamed cartilage tissue on the 
target site for the biopsy of autologous chondrocytes in an OA joint.[80] Another promising source 
for chondrocytes is the nasal tissue. Nasal septal chondrocytes synthesize hyaline cartilage with 
comparable properties to articular cartilage. Studies showed superior performance concerning 
proliferation and chondrogenic potential of nasal chondrocytes compared to their articular relatives 
in vitro and in vivo.[81,82] Potential risks might be the unnatural biomechanical environment for nasal 
chondrocytes when used as cartilage tissue implants due to the lack of mechanical loading at their 
native location. 
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Chondrocytes were historically the primary and first cell resource used in clinical trials of cell-based 
methods. Therefore, almost all currently applied, commercially available and approved cell-based 
products for cartilage repair use chondrocytes (Table 1). Furthermore, several ACI-based methods 
are in phase III clinical trials including NeoCart® (honeycomb bovine collagen type I scaffold 
seeded with autologous chondrocytes), chondrosphere® (small spheroids of neocartilage composed 
of autologous articular chondrocytes with their associated ECM) and Novocart® 3D (biphasic 
collagen type I – chondroitin sulfate scaffold seeded with autologous chondrocytes).[83] 
Table 1 – List of commercially available, approved therapies using chondrocytes for cartilage repair. 1st-
Gen. means first generation ACI, 2nd-Gen. ACI means matrix-assisted ACI with a collagen membrane, 3rd-
Gen. ACI means matrix-induced ACI. Table content adapted from Negoro et al.[84] 
Product name Company Country Approval Remarks 
Carticel® Vericel US 1997(FDA) 






















suspended in EU 
Spherox 
(chondrosphere®) 










MSC are derived from various sources including adipose tissue, bone marrow, peripheral and 
umbilical blood and the synovium while adipose tissue and bone marrow are the mainly used 
sources. They were progressively used in the recent years for a large range of scaffold-based and 
scaffold-free approaches in vitro, in vivo and in several clinical trials, primarily due to their favorable 
features including being multipotent (adipogenic, chondrogenic and osteogenic differentiation 
potential), immunomodulatory and having a high proliferative activity and a low immunogenicity.[85] 
Allogeneic MSCs can have a potential advantage over the autologous version when older patients 
are treated since their cells have reduced proliferative, metabolic and differentiation potential. The 
same is true for MSCs from OA joint tissues which might be negatively preconditioned by the 
surrounding chronic tissue. However, trials with long-term follow-ups are required to prove this 
hypothesis.[86,87] While being embedded into biomaterial-based scaffolds or used as pellet culture in 
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vitro, in clinical trials MSCs are often delivered in suspension via intra-articular injection.[88] General 
problems are cell death after injection as well as the trend towards an unstable chondrogenic 
phenotype resulting in deposition of fibrocartilaginous tissue in in vitro and in vivo cultures, especially 
for bone marrow-derived MSCs. Several attempts were made to circumvent this problem including 
different culture protocols, growth factor stimulation and a selection of subpopulations. Having a 
highly heterogeneous cell population, it has been shown that just a small fraction of MSCs can have 
true chondrogenic potential.[89] Recent approaches use a coculture with chondrocytes leading to 
synergistic effects for both cell types with mutual phenotype stabilization and generally better cell 
performance.[90,91] Furthermore, synovium-derived MSCs are a promising cell source showing 
better results in chondrogenic differentiation than bone-marrow MSCs with the ability of lubricin 
expression.[92,93] It has been recently shown that synovial membrane-derived MSCs originate from 
the so called Gdf5-expressing interzone cells during embryogenic development.[94] It is believed that 
these intersection cells later form the whole synovial joint tissue including the articular cartilage, 
synovium and meniscus. The hypothesis arises that bone-marrow MSCs prefer the growth plate 
chondrocyte pathway after chondrogenic differentiation leading to hypertrophy and endochondral 
ossification while chondrocytes originated from interzone cells follow the articular chondrocyte 
pathway due to their developmental history. A relatively new trend is using MSC secretome-derived 
extracellular vesicles (EV), which are small membrane-enclosed delivery vehicles released by the 
cells containing a cocktail of different cytokines, growth factors, miRNA and other molecules. 
There is a general debate whether the MSCs secretome is the key actor responsible for the 
regenerative properties in MSC-based cell therapy. EVs were used in several studies where they 
showed induction of cartilage repair and anti-degenerative properties in OA cartilage tissue.[95–97] It 
is believed that the miRNA could be epigenetically active inside the target cells explaining some of 
the biological activity of EVs.[98] They would be also potentially helpful in genetic editing 
approaches for cartilage repair being another upcoming trend in cartilage tissue engineering. 
Recently, there were several clinical trials running with (mainly bone marrow-derived) MSC-based 
therapies using ( for the majority) collagen type 1 scaffolds.[85] 
Chondroprogenitor cells: 
Chondroprogenitor cells are an immature and undifferentiated cartilage precursor cell population 
which are more committed to the chondrogenic lineage than MSC’s while having the potential of 
not following the terminal differentiation pathway of mature articular chondrocytes towards 
hypertrophy. Chondroprogenitor cells can be derived from the superficial zone, synovial fluid or 
the synovium. A further advantage is a lower tendency towards dedifferentiation shown by 
prolonged 2D expansion cultures. However, they make up only less than 1% of the cells found in 
mature articular cartilage tissue which is a big limiting factor for extended use.[99]  
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Pluripotent stem cells: 
iPSCs are increasingly investigated as cell source for cartilage tissue engineering. Due to a large 
pool of somatic cells as precursors for the induction of pluripotency, iPSCs are highly abundant. 
Additionally, there are low compatibility and ethical issues with their usage. However, they are not 
primed towards chondrogenic differentiation. The usual differentiation pathway needs an initial 
differentiation step towards mesenchymal-like progenitor cells, which are then differentiated with 
standard chondrogenic differentiation protocols to chondrocytes.[100,101] This is often done in high 
density cultures with embryoid body formation having the risk of cell death for a considerable 
number of cells. Furthermore, there is a general risk for teratoma formation with iPSCs. Despite 
these limitations and the need for standardized differentiation protocols, iPSCs are considered a 
highly promising cell source for future cartilage tissue engineering applications.[102] 
Biomaterials for scaffolding 
The scaffolding materials can have a significant impact on the fate and functionality of the 
embedded cells. Scaffolding materials for cartilage tissue engineering are either of the hydrogel type 
or the porous scaffold type. A general overview of biomaterials and crosslinking chemistries is 
given in section 2.1.2 “Biomaterials for 3D bioprinting”. For cartilage regeneration, collagen type 
I in form of hydrogels, sponges and membranes is among the mostly used scaffolding material. 
Most commercially available scaffold-based products use collagen as base material.[103] Gelatin and 
its methacrylated derivate (GelMa) are extensively applied in in vitro and animal in vivo models due 
to their (like collagen) intrinsic cell binding peptide motifs (RGD) and MMP degradation sites for 
cell-initiated enzymatic remodeling processes.[104] Hyaluronan-based scaffolds are also widely used, 
primarily due to their natural abundance in native cartilage tissue.[105] Chondroitin sulfate being the 
principal component of aggrecan is used for cartilage repair but showed critical behavior at higher 
concentrations when combined with chondrocytes.[106] Generally, most natural hydrogel-forming 
biopolymers need to be modified with functionalities for cell adhesion and additional crosslinking 
sites for further mechanical stabilization due to their intrinsic low stiffness (collagen, hyaluroan), 
unfavorable gelation mechanisms at physiological conditions (gelatin, gellan gum) or risks for 
dissolution over time (alginate). The modification of biomechanical properties can also be achieved 
by forming composite hydrogels made of purely natural or natural/synthetic (biohybrid) polymers. 
The most widely used synthetic polymers for cartilage regeneration approaches are PEG, 
poly(glycolic acid) (PGA), PLA and their copolymer poly(lactic-co-glycolic acid) (PLGA).[107] While 
all of them are bio- and cytocompatible, PEG is an inert, but nondegradable polymer while the 
latter three are biodegradable. Synthetic polymers are not yet used in many clinical trials. However, 
a PEG-fibrinogen system for an AMIC treatment is currently part of a clinical investigation.[108]  
In general, it is difficult to directly compare the performance of the different scaffolding materials 
for cartilage repair. Firstly, most materials are just used in in vitro and animal in vivo models, where 
the implantation is done into artificially created defects. However, OA tissues have a very different 
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setting due to the chronically inflamed environment which may lead to varying outcomes when 
compared to the animal and in vitro models. Secondly, other important factors like cell source, cell 
density, growth factor administration, culture conditions and periods vary significantly among the 
very large number of studies performed for cell-laden hydrogel-based approaches for cartilage 
tissue engineering making it almost impossible to extract the benefits of the scaffolding material 
and compare them with other materials from different studies.[109] Thirdly, there is often an 
inconsistent reporting of analytical data which adds to the list of problems to make informative 
statements.  
Signaling molecules and other biochemical cues 
A variety of growth factors is used that induce and promote chondrogenic differentiation in 
different cell types. The most common ones are members of the TGF-ß superfamily like TGF-ß1-
3 and BMPs, as well as IGFs and FGFs.[10] TGF-ß1 and -ß3 are generally used for MSC 
chondrogenesis. BMP-7 is used for chondrogenic differentiation of cell-laden hydrogels while 
BMP-2 and GDF-5 are preferably applied for the formation of osteochondral constructs due to 
their initially chondrogenic and later osteogenic induction potential. IGF-1 is used to ameliorate 
both the proliferation of chondrogenic cells and the cartilaginous matrix production. FGF-2 is 
often used for enhancement and stabilization of the chondrogenic potential and proliferation of 
MSCs and chondrocytes during expansion culture. All the mentioned growth factors play pivotal 
roles in cartilage development and homeostasis and have high potential for cartilage repair.[110] A 
growing trend is the combination of several growth factors for cartilage tissue engineering, but 
there is still a poor understanding of the effects of combined growth factor applications. One study 
showed significant enhancement in cartilage matrix production when IGF-1, TGF-ß1 and BMP-7 
were applied together.[111] Furthermore, combinatorial approaches can also be used to control and 
minimize hypertrophic development during chondrogenic differentiation. A dual growth factor 
supply strategy used FGF-9/-18 to inhibit and delay hypertrophy in MSCs.[112] Growth factors can 
be delivered via different ways including free-soluble form in medium, physical entrapment into 
and covalent bonding to the scaffolding material, micro- and nanoparticles and gene delivery.[109] 
Incorporation and microsphere delivery of growth factors is especially helpful for in vivo models 
where no external supply can be maintained like in in vitro cultures. 
Besides growth factors, small molecules such as dexamethasone and kartogenin, a newly identified 
component for chondrogenesis are used to promote chondrogenic differentiation while 
dorsomorphine was applied for the inhibition of hypertrophy-related pathways.[113,114] Anorganic 
particles including hydroxyapatite, tricalcium phosphate, laponite and wollastonite can be used as 
inducer of osteogenic differentiation for osteochondral constructs and modifier of rheological 
properties which is important for 3D bioprinting applications.[109] 
 




Articular cartilage homeostasis is highly dependent of mechanical loading. Chondrocytes have 
mechanosensitive receptors that induce matrix production under stimulus. Furthermore, cycles of 
compression and release are important for nutrient supply and metabolic waste disposal. Therefore, 
mechanical stimuli in form of compression, tension and fluid-induced shear were applied to 
enhance cartilage ECM deposition of chondrocytes and chondrogenic differentiation of 
MSC’s.[115,116] In addition, culture under hypoxic conditions has been shown to improve 
chondrogenesis and prevent hypertrophic changes in chondrocytes and MSC, thus mimicking the 
hypoxic environment in native articular cartilage proved to be supportive.[117]  
 
2.1.6 Bioprinting for cartilage tissue engineering 
The layered architecture and the lack of vascularization make articular cartilage an interesting target 
for 3D bioprinting applications. Many studies using inkjet, extrusion and laser-based printing report 
3D bioprinting approaches for articular cartilage tissue engineering.[19,118–120] Extrusion bioprinting 
is the most common printing technique, while alginate and the methacrylated versions of collagen, 
hyaluronan and gelatin were mainly used as bioink scaffold materials. PEG is often applied as 
additional crosslinker for tailoring mechanical properties. Applied biochemical cues are the same 
as presented in the former section. Most bioprinting studies report a relatively high cell viability of 
>80%. Despite having similar issues like casted constructs concerning fibrocartilage formation and 
tendency towards hypertrophy of chondrocytes and MSC’s, the combination of PCL-derived grid 
structures as mechanical stabilizers with printed cell-laden hydrogels forming bioprinted hybrid 
scaffolds proved to be a significant advantage which led to mechanical properties comparable to 
articular cartilage.[121] Some reports present the fabrication of printed constructs with a layered, 
cartilage-mimicking architecture.[11] However, the recapitulation of a fully biomimetic and -
functional zonal hydrogel was not achieved yet and remains one of the core targets of advanced 
biofabrication techniques for cartilage repair. Ultimately, extensive clinical trials are still needed to 
demonstrate any significant advantages of bioprinted scaffolds over casted constructs and common 
therapies. 
 
2.1.7 Future trends in cartilage tissue engineering 
Despite the efforts of the last decades in cartilage tissue engineering, it is still a long way towards 
fully cell- and biomaterial-based biofunctional cartilage constructs. Several areas demand further 
investigation in order to make progress in cartilage tissue engineering. Particularly important is the 
focus on the careful selection of cell subpopulations, especially for MSC’s to reduce the probability 
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of adverse developments like hypertrophy and fibrocartilage formation.[122] More insight in the 
influence of the MSC secretome on chondrogenesis and cell therapies is highly interesting and 
demanded. Here, MSC-derived EV will probably play a more important role in the future.[123] A 
growing trend is the genetic modification of cells to enhance the chondrogenic potential or to 
counteract degenerative processes in the OA tissue after implantation.[124] This goes along with a 
more profound understanding of the biochemical and -mechanical mechanisms of OA 
development and progression to derive appropriate strategies and therapies. Additionally, 
understanding the complex interactions of combinations of different growth factors with cells from 
diverse sources embedded in a variety of biomaterials is crucial. Combinatorial approaches will 
probably play an important role in finding answers to these questions.[125] The application of 
bioreactors to exercise mechanical stimuli, hypoxia and other cues will most likely be the standard 
way of operation in order to fabricate sophisticated tissue constructs and models.[126] Finally, more 
emphasis will be on the development and understanding of osteochondral tissue systems to 
recapitulate the complex environment of the synovial joint, particularly the interaction of the 
articular cartilage with the subchondral bone. Bioprinting and other biofabrication methods may 
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2.2 3D bioprinting 
The progress in the technological development of the last decades gave rise to the since then 
strongly growing field of additive manufacturing (AM), which is a superordinate concept for 
different three-dimensional (3D) manufacturing techniques. The concept of 3D printing being one 
of the core AM methods was originally reported and patented by Charles Hull in 1986 when he 
described a procedure for layer-by-layer material deposition to produce 3D objects with controlled 
shape and architecture.[127] With further advancement in technology and substantial progress in the 
research fields of cell biology and material science the first reports of 3D bioprinting were 
eventually communicated in which these different disciplines were applied together.[128] 3D 
bioprinting can be therefore defined as depositing biocompatible materials loaded with living cells 
in a controlled 3D fashion to create biofunctional constructs.  
In combination with the booming field of tissue engineering, 3D bioprinting had have a staggering 
development in the last 10 years indicated by a strong increase in scientific publications from about 
40 during the whole decade of the 2000s to more than 336 just in 2018 according to the Web of 
Science database for the key word “bioprinting”. Furthermore the global economic market size for 
bioprinting was valued already at USD 682 million in 2016 while having a projected compounded 
annual growth rate (CAGR) of 18.4% until 2024.[129] The accelerating establishment of a whole 
tissue engineering “value chain” starting from basic applied in vitro research over in vivo studies and 
clinical trials towards a ready-to-be-marketed product where 3D bioprinting is expected to play a 
pivotal role is fueled by a high demand for custom-made, biomimetic and highly specialized 
biomedical constructs with potential applications in the various fields of (organ) tissue engineering, 
pharmaceutical drug testing as well as fundamental and applied biomedical research.[130] 
In the following part there will be a presentation of the most important 3D bioprinting techniques 
with the mainly used chemical and biological materials and their actual employment being 
represented by key examples of the mentioned application areas. For each section, the recent trends 
and a potential outlook is given. 
 
2.2.1 Bioprinting techniques  
The general procedure for bioprinting follows a 3-step process: a pre-, normal and post-
processing step.[120] The pre-processing step is the planning phase where the dimension, 
structure and form of the to-be-printed construct are determined and the required materials and 
conditions are selected. Aside of various software tools for designing 3D models of scaffolds 
having a desired architecture, different imaging techniques like magnetic resonance imaging (MRI) 
or computer tomography (CT) can be used to obtain data for patient-specific 3D models in case 
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of personalized constructs. The materials including appropriate biomaterials, cells and other 
biochemical molecules are then selected to meet the required properties and functions. The 
combination of all printable components is often referred to as bioink. The following processing 
step involves the preparation of the materials and the actual printing process. Afterwards the 
printed construct is then maintained and appropriately treated for the target application in the post-
processing phase. 
Bioprinting techniques 
The different 3D bioprinting techniques can be generally divided into four distinct categories 
(Figure 4):[131] 
• Droplet-based printing 
• Laser-based printing 
• Extrusion-based printing 
• Stereolithography 
Droplet-based printing, also referred to as drop-on-demand printing, uses droplet-forming 
methods in order to dispense the bioink in a droplet-by-droplet fashion onto the target substrate. 
The techniques to generate the droplets determine the subtypes which are generally segmented into 
inkjet printing and other droplet-based printing methods. For inkjet bioprinting being the mainly 
used type among the droplet-based methods a thermal[132], piezoelectric[133] or electrostatic[134] trigger 
installed in the pipette tip is used to produce a localized and timely controlled pressure which forces 
the bioink to quickly exit the nozzle in a droplet-like shape if the surface tension at the outlet is 
surpassed. Thermal triggers with a localized heating element produce a quickly expanding gas 
bubble whereas piezoelectric actuators expand as the result of applied electricity. The inkjet 
techniques have a fast (up to 10000 droplets per second)[135] and precise (about 50 µm)[136] printing 
procedure with high cell viability in common but possess limited applicability when (highly) viscous 
solutions and high cell concentrations are used which may lead to clogging problems.[137] Further 
droplet-based techniques including acoustic[138], microvalve[139] and electro-hydrodynamic jetting 
(EHD)-based[140] printing represent relatively new and therefore less intensively studied methods 
which use acoustic actuation of a pooled bioink, a combined action of pneumatic pressure and 
electromechanic valving as well as a high voltage electric field between the nozzle of the pipette 
and the substrate as droplet generators, respectively. EHD- and acoustic printing deliver also fast 
and highly precise printing results but apply relatively high mechanical and electrical forces onto 
the cells leading to potential viability issues.[141] Microvalve printing on the other side shares similar 
problems with the inkjet techniques while having no other significant advantages so far.[142] 
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Figure 4 – Schematic representations of inkjet (A), laser-based (B), extrusion-based (C) bioprinting and 
stereolithography (D). Image adapted from Huang et al.[131] 
Laser-based printing uses a different approach for biomaterial deposition, mainly characterized 
by avoiding the use of a nozzle or printing pipette. The bioink is adsorbed onto a ribbon which is 
usually coated with a gold or titanium layer for laser energy absorption. When a controlled laser 
pulse is irradiated on the ribbon, a high-pressure bubble is created in the bioink which is located 
on the opposite site of the ribbon by energy transfer from the laser to the solution. This results in 
ejecting a droplet towards an underlying collector substrate.[143] Due to the precise control of the 
laser pulse length and irradiation area, droplets with very high accuracy and printing frequency are 
achieved, so sharing similar characteristics with inkjet printing. But in contrast to droplet-based 
printing methods the contact- and nozzle-free printing feature of laser-assisted bioprinting allows 
for printing of very high cell densities (up to 108 Mio cells/ml) and bioinks with a broad viscosity 
range.[144,145] On the other side, laser-based printing is a high cost method with a time-consuming 
sample preparation phase which has generally limited capability for scaling up in order to produce 
higher quantities of tissue in a reasonable amount of time.[146] Another disadvantage is caused by 
the laser pulses which may have a negative impact on the cells and lead to possible abrasion of the 
metal coating producing potentially cytotoxic metal nanoparticles.[143,147]  
Extrusion-based printing, often referred to as microextrusion, uses compressed air or 
mechanical forces induced by a piston or a screw to dispense the bioink in a continuous flow out 
of the nozzle.[148] This technique allows for printing of bioinks with different levels of viscosity and 
enables to print the highest possible cell concentrations among all 3D bioprinting types. Further 
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advantages including large material deposition rates for a variety of printable materials and 
therefore rapid building up of 3D human-scale tissues constructs make microextrusion printing the 
currently mostly used 3D bioprinting method.[137,149] However, these intrinsic benefits come with 
the trade-off to apply often high pressures in case of very viscous solutions resulting in a reduced 
cell viability (~ 40%). In addition, extrusion printing has generally the lowest resolution (100 µm) 
when compared to the other bioprinting techniques.[150,151] Variation in nozzle diameter or the use 
of low viscous and highly shear-thinning materials can attenuate these problems but lead to higher 
shear-forces and thereby cellular damages or limited options of printable bioink materials, 
respectively. 
Stereolithography uses photopolymerization to create 3D objects. The bioink being a 
photopolymerizable cell-laden resin is cured by a computer-controlled (UV-) light source in 
motion. By vertically moving the bioink stage, the light source “draws” layer-by-layer a desired 
structure into the resin solution yielding the “printed” 3D object.[152] Alternatively, exposure of a 
non-moving UV source on an array of individually controllable micromirrors which reflect the light 
on to the bioink (this method is called Digital Micromirror Device-Projection printing [153]) leads to 
a full layer curing at once. Stereolithography in general offers the highest achievable resolution 
(down to 200 nm) when two-photon-induced polymerization is applied.[154] Being a nozzle-free 
technique, high cell concentrations also display no problem while only bioinks with low viscosity 
are applicable. The disadvantage is clearly the necessary use of potentially cytotoxic photoinitiators 
and the UV-light exposure on the cells, which may cause DNA damage and cell viability issues. 
Together with a relatively low number of suitable materials and an extended post-processing phase 
these issues display the main reasons why stereolithography remains a little used 3D bioprinting 
method despite its early development.[155] 
Choosing the right printing technique depends finally on many different parameters including the 
size, structure, resolution and quantity of the target 3D construct within its application area 
combined with a careful selection of usable bioink materials. All the mentioned techniques have 
their strengths and weaknesses which can be circumvented and turned into synergistic effects when 
used in parallel. This trend is expected to be a potential future for the development of advanced 
3D bioprinting methods.[120,156] 
 
2.2.2 Materials for Bioprinting 
Bioink components can be divided into the scaffold material, cells and biochemical cues.[131] 
The scaffold materials have to be classified either as cell containing or non-cell containing. Cell-
containing scaffold materials range from hydrogels made of either synthetic or natural polymers, 
synthetic-natural biohybrid polymer mixtures to decellularized ECM-derived materials. The 
important requisite for these materials is them being biocompatible and ideally -functional. 
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Biodegradability can also be an important property depending on the application. Furthermore, the 
crosslinking and polymerization chemistry need to be cytocompatible. The role of these materials 
is to provide an artificial and engineered matrix environment for the cells to ensure their biological 
functioning. Non-cell containing scaffold materials do not allow living cells to be directly 
incorporated during the printing process due to often harsh processing conditions like the use of 
organic solvents or high melting temperatures. These materials are also required to be 
biocompatible but only after the processing step cells can be seeded onto them. Therefore, these 
scaffolds are often used as mechanical supports and shaping constructs which can be filled and 
loaded with cell-containing bioinks.[157,158] This category of materials include synthetic polymers like 
poly(lactic acid) (PLA)[159], poly(caprolactone) (PCL)[160] and polyether ether ketone (PEEK)[161] and 
ceramics like tricalcium phosphates and hydroxyapatite.[162] Latter can also be mixed in powder 
form with cell-laden hydrogels to create composite bioinks.[163] 
Hydrogels represent the mostly used bioink scaffold material for 3D bioprinting applications. PEG, 
polyacrylamides, and poloxamers (e.g. Pluronic) are among the most common synthetic polymers 
used for cell-laden, bioprintable synthetic hydrogels.[164,165] Even though they are bio- and 
cytocompatible, they have no intrinsic biofunctionality and -activity which are important properties 
of ECM-mimicking artificial cell environments. Therefore, a wide range of natural polymers is used 
to introduce functional moieties. These materials include poly(amino)saccharides like agarose, 
alginate, chitosan and gellan gum, glycosaminoglycans (GAGs) like hyaluronic acid and chondroitin 
sulfate and proteins like collagen, elastin, fibrin, gelatin, and silk fibroin.[166]  
In order to print a dimensionally stable construct, the scaffold material must be transitioned from 
a liquid-like phase during the printing step into a more solid-like state after material deposition in 
a relatively short period of time. There is a variety of ways to accomplish this which are also often 
linked to certain printing methods. Highly viscous or shear-thinning bioinks are for example 
required for extrusion-based printing and possess an intrinsic shape-stability which can be further 
secured by chemical modification with photoreactible functional units for a post-processing 
photocrosslinking step. Methacrylated forms of gelatin (GelMA) and hyaluronic acid are examples 
for often used materials of this type.[104,167] For inkjet printing, low viscous polymer solutions are 
required which demand much faster crosslinking kinetics for the fabrication of constructs with 
high shape fidelity. Therefore, cytocompatible in situ reactions like Michael-type additions of 
chemically modified polymers with thiol groups and activated unsaturated functionalities like 
acrylates, maleimides or vinyl sulfones are used in these cases. Besides chemical covalent bondings, 
enzymatical, ionic, physical and supramolecular crosslinking are additional ways to solidify the 
bioink. Fibrin-based hydrogels are enzymatically polymerized by mixing a fibrinogen-containing 
component with a thrombin solution[121], alginate-based materials use divalent cations like Ca2+ or 
Sr2+ for ionic crosslinking[168] and collagen or elastin have a sol-to-gel phase transition at an 
increased temperature to form physical hydrogels[169]. Additionally, the modification of polymers 
with guest-host functionalities like cyclodextrin-adamantane moieties or complementary DNA 
oligonucleotide-polypeptide interactions give rise to supramolecular bonding methods.[170,171] In 
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order to further modify and control the mechanical and biophysical properties of the scaffolding 
material, natural and synthetic polymers can be mixed to create biohybrid bioinks as well as the 
introduction of orthogonal crosslinking functionalities allow for additional polymerization options 
after the initial crosslinking leading to interpenetrating polymer networks.[172]  
The recent progress in scaffold material development lead to the introduction of decellularized 
ECM (dECM) and shape- and function-changing materials in bioprinting, latter also often referred 
to as 4D bioprinting. Originating from a broad range of tissues including heart, liver, cartilage or 
skin mainly produced from a porcine source, dECM offer the benefits of a naturally derived 
scaffolding material often being the original environment for the target cells to be used and 
therefore being highly biomimetic compared to artificial matrix substitutions. However, the 
decellularization process can lead to often unpredictable changes in the composition and properties 
of the native ECM and suffers from batch-to-batch variations like all naturally derived 
biomaterials.[173] On the other hand, 4D bioprinting scaffold materials provide new ways for the 
introduction of additional functionalities. These materials possess the intrinsic potential of 
changing their form or function under the influence of external stimuli including current, heat, 
electric and magnetic fields, osmotic pressure, ultraviolet light and further energy sources.[174] 
Besides the various possibilities for suitable scaffold materials, cells can be also presented in 
different ways. Most commonly, cells are suspended and homogenized into the bioink prior to the 
printing step. Since every cell type has different necessities for an optimal functioning, cells can 
also be printed in form of tissue spheroids and cell pellets.[175,176] Depending on the type of cell, 
these pre-aggregated constructs introduce the cellular material into the scaffold in a preferred 
condition leading to enhanced cell performance which may be not as achievable with 
homogeneously suspended cells. In case only cell aggregates are printed and stacked on each other, 
this approach is often referred to as “scaffold-free” bioprinting. Ultimately, the selection of the 
scaffold material and crosslinking method is highly influenced by the desired cell type to be used 
and with it the target tissue or tissue model (Figure 5).[149] The cells need to be provided with an 
extracellular microenvironment allowing them to exercise their biological function in the best 
possible way. This includes proliferation, differentiation, cellular aggregation, matrix production as 
well as secretion and binding of bioactive molecules. Therefore, the bioink as biomimetic artificial 
ECM is needed to be cell-adhesive, degradable for matrix remodeling and capable of binding and 
stabilizing growth factors and other soluble cues.  




Figure 5 – Overview of different parameters and their interaction that influence the selection process of 
bioinks and printing methods for suitable biofabrication approaches. Image adapted from Malda et al.[149]  
In order to fulfill these requirements, biochemical molecules and other cues can be 
incorporated into bioinks to complement the functionality of the scaffold material. Growth factors, 
cytokines and other bioactive small molecules act as cell-instructive cues directing the 
differentiation, proliferation and migration of cells and can be introduced by simple mixing with 
the bioink, but also by covalent attachment or various delivery systems (e.g. micro- and 
nanoparticles composed of growth factor-binding materials which can release the loaded 
biomolecule over time).[177,178] Hydrogels having no adhesion sites can be modified with cell-
adhesive peptides including RGD and IKVAV motifs.[179] To further increase the potential for cells 
to influence their microenvironment, the bioink degradability can be tuned by incorporation of 
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Future trends in materials for bioprinting 
After the initial development of the established printing techniques and the introduction of natural 
and synthetic polymers for hydrogel printing, the recent trend in advancing 3D bioprinting points 
towards the combination of various methods and materials to enable the fabrication of more 
sophisticated tissue constructs and models. Multicomponent and -phasic materials including more 
advanced and complex natural-synthetic biohybrid hydrogels, dECM-based and nanocomposite 
bioinks as well as stimuli-responsive printing materials for 4D printing combined with 
multifunctional bioprinting devices are the most promising approaches in the recent future.[172,181–
183] Supramolecular crosslinking is likely to become more important due to its great utility, especially 
for extrusion-based printing which is considered to remain the most important core printing 
technique in the future.[155] The rise of organoid tissue engineering makes it also a promising 
candidate to be combined with 3D bioprinting methods.[184] Overall the fabrication of organs, 
tissues and in vitro models being highly complex and unique in their architecture and functionality 
demands for more sophisticatedly custom-tailored designs which are specifically derived for a 
selected target application. 
 
2.2.3 Applications in tissue engineering and regenerative 
medicine  
The application areas of bioprinted objects can be generally classified into two categories: 
organ/tissue constructs and in vitro models.[185] Organ and tissue constructs aim to replicate 
a fully functional organ or tissue substitute which can be implanted into the body to replace a 
malfunctioning or damaged organ/tissue or parts of it. Printed in vitro models are trying to 
reproduce the hierarchical structure and function of organs and tissues in relatively small 3D 
constructs with high reproducibility and quantity in order to create a platform for high-throughput 
drug and toxicity screening. They are also meant to fill the gap between 2D cell culture and in vivo 
animal models while aiming to reduce the latter to a possible minimum. Furthermore, in vitro 
models are extensively used in cancer research and to deepen the fundamental understanding of 
the mechanisms of developmental processes.[130] 
Besides this classification, vascularization is an important and critical characteristic of organs and 
tissues for nutrient and gas transport as well as metabolic waste disposal and therefore essential for 
both tissues and models. Different methods and strategies for 3D bioprinting were developed to 
tackle this general problem of 3D cell culture constructs.[186] These include the indirect printing 
using sacrificial materials or fugitive inks and the direct printing of interconnected channels and 
tubular structures.[187] Sacrificial and fugitive inks like carbohydrate glass, gelatin and pluronic have 
orthogonal and reversible gelation chemistries compared to the bulk hydrogel which allow them to 
be dissolved after being printed and embedded into the surrounding scaffold material.[188,189] The 
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endothelial cells forming the inner cell layer of blood vessels are either seeded afterwards by 
perfusion culture or are directly mixed into the fugitive ink. Stereolithography-based methods are 
used for direct printing of interconnected channels but still lack the possibilities to produce 
complex vascular networks. Direct printing of tubular structures can be achieved by printing 
hollow alginate-based core/shell cell-laden hydrogel tubes using a coaxial extrusion method.[190] 
Further approaches employ supportive microparticle-based slurries made of gelatin or poly(vinyl 
alcohol) as “inverse sacrificial materials” where the vascular structure-forming material is directly 
“written” into the 3D support which is later being removed.[191,192] Additionally printing of tissue 
spheroids and cell aggregates composed of one or several cell types which subsequently self-
assemble into vascular tubes is another way.[193] Despite these efforts, it is still challenging to 
fabricate fully functional blood vessels and integrated microvascular structures. Especially the 
multicellular hierarchical architecture of larger blood vessels remains difficult to be reproduced 
with biofabrication methods. 
One of the main purposes for 3D bioprinting is the fabrication of organ and tissue substitutes. 
The promising perspective lies in the various possibilities of spatially controlled deposition of a 
multitude of bio- and cellular materials in order to replicate the complex architecture of living 
matter. In the last decade, a wide range of target tissues were addressed by 3D bioprinting 
techniques including bone, cartilage, heart, liver, muscle, neural, skin and many others to a lesser 
extent.[119,120,137] 3D bioprinted constructs for bone tissue engineering often use mixtures of 
natural or natural-synthetic hybrid hydrogels with embedded cells like bone-marrows derived MSCs 
or osteosarcoma cells.[194,195] As biochemical cues, osteoinductive materials including 
hydroxyapatite, biphasic calcium phosphate and bioactive glass microparticles as well as growth 
factors like bone morphogenic factor 2 (BMP-2) were incorporated into the bioinks.[196,197] A 
different, developmental-oriented approach used a bone-marrow MSC-laden, RGD-modified 
alginate hydrogel which was bioprinted alongside PCL fibers to fabricate in vitro a provisional 
cartilaginous construct which became hypertrophic in vivo and eventually resulted in bone 
formation by endochondral ossification.[198] For cardiac tissue engineering, cardiomyocytes and 
their progenitor cells are used to produce 3D printed myocardial tissue with high cell viability and 
an observed full-construct contraction in a variety of scaffold materials.[199,200] A spatially-controlled 
deposition of MSCs and human umbilical vein endothelia cells (HUVEC) with a laser-based 
printing technique for a cardiac patch with potential application in case of myocardial infarction 
resulted in significant higher vascularization compared to a control with randomly deposited cells 
indicating the importance of selective cell patterning and the capability of bioprinting to tackle this 
issue.[201] Cell-laden collagen-based hydrogel materials are commonly used for bioprinting of skin 
tissue. Layer-by-layer printing of embedded cells including dermal fibroblast and keratinocytes 
produced biomimetic skin-like tissue constructs with inkjet and laser-based bioprinting 
methods.[202–204] Unlike the printing approaches for complex organs e.g. heart and liver, which 
despite significant effort and progress in the recent years are still in the proof-of-concept phase for 
the majority of cases, skin bioprinting is relatively successful and has the potential for impending 
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clinical application while the integration of sweat glands and hair follicles remains a challenging 
task to be solved.[119,130]  
The mentioned examples for organ and tissue bioprinting represent only a very small selection of 
many studies conducted in the last decade. For further information and insight, a review written 
by Vijayavenkataraman et al. is highly recommended.[120]  
 
General trends in 3D bioprinting 
Besides the already mentioned future trends in the development of new techniques and materials 
for 3D bioprinting, some additional aspects may become more relevant in the future. In situ 
bioprinting where construct fabrication is directly performed on the patient during an operation 
may be potentially available and feasible with further progress in the bioprinting field.[205] The use 
of induced pluripotent stem cells (iPSC) as major cell source for different organ and tissue 
applications is a promising approach concerning the shortage of sufficient cells necessary for the 
fabrication of large-scale tissues due to the often slow proliferation behavior and potential 
dedifferentiation issues of differentiated cells.[206] Finally, vascularization will continue to be a major 
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2.3 The starPEG-heparin hydrogel system 
In this thesis, an inhouse developed heparin-based hydrogel system was used as scaffolding material 
for the chondrogenic differentiation of bone marrow-derived MSCs. This hydrogel has been shown 
to be a suitable biomimetic matrix substitute for several 3D cell culture applications.[207–209] Being a 
biohybrid scaffolding material composed of a maleimide-functionalized bioactive heparin 
component which is immobilized via a bioorthogonal Michael-type addition crosslinking reaction 
with thiol-functionalized 4-arm PEG polymers (starPEG), the resulting hydrogel has 
biocompatible, -degradable and -functional properties.  
Heparin is a naturally derived, highly sulfated GAG which is produced by basophils and mast cells 
in several mammalian tissues including lung, liver and mucosa.[210] Having the highest negative 
charge density of all biopolymers, heparin is capable of readily binding and stabilizing a broad range 
of growth factors and chemokines via electrostatic interaction due to their often positive surface 
charges. The heparin-based hydrogel can have the potential to be particularly interesting for 
cartilage matrix biomimics since articular cartilage being itself a tissue with a relatively high negative 
charge density due to a 5-10 % (w/w) aggrecan content which is primarily composed of sulfated 
GAGs (chondroitin sulfate, keratane sulfate). Therefore, heparin might add to a high water 
retention capacity which leads to a compressive resilience in engineered artificial cartilage 
constructs when combined with a strong cell-deposited collagen network. Furthermore, TGF-ß1 
is used for chondrogenic differentiation of human bone marrow-derived MSC’s in thesis. It has 
been shown that TGF-ßs bound to heparin and heparan sulfate can result in an enhanced growth 
factor activity.[211–213] 
One of the important features of this hydrogel system is the modular material design. 
Biodegradability, mechanical properties, bioactivity and -functionality can be independently altered 
to deliver tailored artificial ECM microenvironments for 3D cell culture applications. Heparin can 
be controllably modified with up to 8 maleimide groups which can either be used for crosslinking 
or covalent bonding of a variety of bioactive, cysteine-containing adhesion peptides like RGD or 
IKVAV motifs. Selective desulfation or substitution of heparin by maleimide-functionalized 
starPEG can alter the activity and concentration of the bioactive component. Enzymatic 
degradability can be tuned by combining starPEG polymers modified with cysteine-containing 
MMP-sensitive peptide linkers (starPEG-MMP) with non-degradable thiol-functionalized starPEG 
for crosslinking reactions (Figure 6A). The hydrogel stiffness can be adjusted by varying the molar 
ratios of starPEG to heparin (γ) which results in different crosslinking degrees. Finally, the 
preloading of heparin-binding growth factors at different concentrations complements the toolbox 
of possibilities for a tailor-made hydrogel formation.  
2   Fundamentals 
 
32 
Figure 6 – Schematic representation of the starPEG-heparin hydrogel chemistry. Michael-type addition of 
orthogonally protected dicysteine-containing, MMP-sensitive peptides to maleimide-functionalized 
starPEG results in MMP-degradable starPEG crosslinker polymers (A). Modification of heparin with N-(2-
Aminoethyl) maleimide via EDC/NHS coupling and covalent addition of RGD peptide for 
biofunctionalization (B). Mixing of different ratios of heparin-maleimide to starPEG and addition of cells 
and biochemical cues to form cell-laden, biofunctional starPEG-heparin hydrogels with tunable mechanical 
properties (C). Image adapted from Tsurkan et al.[209] 
In order to avoid inhomogeneous hydrogels after mixing of both gel precursor solutions due to 
early gelation, the pH can be adjusted to control the speed of the Michael-type addition reaction. 
By lowering the pH, the equilibrium between the deprotonated thiolates being the reactive 
nucleophiles and the thiol groups is shifted towards the latter resulting in a slower gelation time.   
Overall, the modular starPEG-heparin hydrogel is a promising candidate to support 3D MSC-
based chondrogenesis. The variation of different material parameters can lead to a better 
understanding of the scaffold-based chondrogenic differentiation of MSCs and help to fabricate 




















3 Materials and Methods
3.1 The inkjet printer Nanoplotter 2 
In this thesis, an inkjet printer was used for creating 3D bioprinted and cell-laden hydrogel 
scaffolds. The Nanoplotter 2.1 from the German company GeSiM mbH was equipped with a 
custom-made dual pipette printing head for two-component hydrogel printing. The printing 
pipettes used piezoelectric actuators to eject liquid droplets with a volume of about 700 pl per 
droplet and up to 1000 droplets per printing spot. A target-designing software was used to create 
spot-based patterns as design basis to print layered hydrogel constructs. During the printing 
process, the pipettes were adjusted into a V-shape position in order to allow fusion of the ejected 
liquid droplets on the underlying substrate (Figure 7B). The dual inkjet printing method allows 
plotting of two-component hydrogel systems with fast polymerization chemistries like the applied 
Michael-type thiol-maleimide addition-based crosslinking scheme. The substrate was positioned 
onto a water-cooled plate to prevent evaporation while being surrounded by a humidified chamber. 
The pipettes were directly attached to a pump system via plastic tubes which contained ultrapure 
water as system liquid. This was used to maintain the liquid level of the uploaded polymer solutions 
during the printing process and also for pipette washing and cleaning steps. The polymer solutions 
were stored in a 96-well plate located next to the washing station. Furthermore, a stroboscope was 
installed in order to visualize the droplet ejection behavior which could be adjusted by the applied 
voltage and pipette geometry. 
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Figure 7 – Nanoplotter setup with printing chamber and attached pumps for system liquid transport (A). 
Schematic representation of V-shaped dual pipette printing setup, pipettes are loaded with thiol- and 
maleimide-functionalized gel precursor solutions which form a hydrogel upon contact on the substrate 
surface (B). 
 
3.2 Printing of 3D hydrogels 
3.2.1 Maleimide-functionalization of glass surfaces 
In order to immobilize printed hydrogels, glass coverslips were functionalized with maleimid 
groups. Firstly, the surfaces were pre-cleaned with ultrapure water (MilliQ water) and further 
sonicated in ethanol for 30 min. Subsequently the coverslips were treated with RCA cleaning 
solution (consisting of H2O + H2O2 + NH3 with a volume ratio of 5:1:1) for 10 min at 70°C and 
washed 3x with MilliQ. The clean coverslips were immersed into a 20 mM solution of 3-
aminoethyltriethoxysilane (Sigma Aldrich, Germany) dissolved in a mixture with 90% (v/v) 2-
isopropanol and 10% MilliQ for 2h immediately after the washing steps. Thereafter the coverslips 
were dried at 120°C for 2h. Right after cooling down, a 0.3% (w/w) solution of poly(ethylene-alt-
maleic anhydride) (PEMA) in acetone/tetrahydrofurane (1:2) was spin coated onto the amino-
functionalized glass surface followed by an annealing step at 120°C for 2h. The coverslips could 
be stored or used for additional modifications at this point. In case of storing, a reactivation of 
possibly hydrolyzed maleic anhydride groups by heating the coverslips at 120°C for 2h was 
performed prior to further treatments.  
For maleimide functionalization, PEMA coated coverslips were immersed into an acqueous 
solution of about 0.4 µM 2-aminoethylmaleimide (0.1 mg/ml) for 1h at room temperature, then 
washed twice with MilliQ and dried under a nitrogen stream. 
A B 
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3.2.2 Fabrication of zonal hydrogel scaffolds with inkjet printing  
The preparation for printing of two-component hydrogels involved 2 steps: 
a. Setting up the hard- and software of the Nanoplotter 2.1 
b. Preparation of the polymer solutions as gel precursors 
a. Setup of the Nanoplotter 
The Nanoplotter and the connected pump were switched on and the related software programs 
(NPC 16.exe and spotfrontend.exe) were loaded. The liquid waste container was emptied, and the 
system liquid container was filled with MilliQ water. Furthermore, the working plate cooler and the 
dispenser of the humidifier were switched on. Then the printer was initiated with NPC 16 and the 
piezoelectric pipettes were installed, filled and washed with system liquid. A printing pattern with 
the desired settings was programmed with spotfrontend.exe and loaded into NPC 16. A maleimide-
functionalized coverslip was placed onto the working plate and the 96-well plate with the polymer 
solutions was put in place. The printing process was then started with NPC16. 
b. Preparation of the gel precursor solutions 
A variety of two-component gel compositions and systems are printable with the Nanoplotter 2. 
In this section, only the preparation procedure for the primarily used composition of non-cell 
containing hydrogels (non-MMP degradable starPEG-heparin hydrogel, γ = 1.5) is shown. 
Different compositions and gel modifications are described in the sections 3.2.3 and 3.3.3.  
For hydrogel printing usually 150 µl of the gel precursor solutions were prepared. 6.72 mg of HM6 
(heparin functionalized with 6 maleimide groups per molecule) and 7.12 mg PEG-SH are dissolved 
separately in each 150 µl phosphate-buffered saline (PBS). Then the pH was adjusted to 7.2 with 1 
M HCl or NaOH in both solutions to arrive at a gelation time of about 1 sec. If fluorescent labeling 
was desired, an Atto-maleimide dye was thoroughly mixed to the PEG-solution to arrive at a 
concentration of 0.5 µg/ml. Subsequently the solutions were transferred into a 96 well plate to be 
ready to be used for printing. 
 
3.2.3 Bioprinting of cell-laden hydrogel structures  
The operational procedure for printing cell-laden hydrogels remained the same as for non-cell 
containing hydrogels. 
In order to incorporate cells into the hydrogel during the printing process, the cells suspended in 
medium were added to both gel precursor solutions. Additionally, 4-arm PEG polymers modified 
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with MMP-cleavable peptide linkers (PEG-MMP) as well as RGD peptides were added to the 
polymer solutions to facilitate cell rearrangements and cell attachment to the gel matrix, 
respectively.  
For chondrogenic differentiation experiments, the cell proliferation and life/dead assays 
of printed hMSC and other cell types, a 75% MMP-cleavable (indicating 75% of PEG-polymers 
were PEG-MMP) starPEG-heparin hydrogel modified with 1 mol RGD per 1 mol heparin and 
γ=1.5 was used. For the heparin solution, 6.72 mg HM6 were dissolved in 41.2 µl PBS and then 
supplemented with 8.8 µl of an aqueous solution of 50 µg/µl RGD peptide. Thereafter 100 µl of 
cell suspension (cell concentration at 1.2x the final cell concentration in the hydrogel) were added 
and mixed gently. For the PEG solution, 1.78 mg PEG-SH and 7.81 mg Peg-MMP were dissolved 
separately in each 25 µl and then combined. 100 µl of cell suspension (cell concentration at 0.8x 
the final cell concentration) were added and gently mixed.  
For the hMSC migration experiment, a 100% MMP-cleavable hydrogel was used. Furthermore 
HM6 was substituted by 6O,N-desulfated HM6 (dsHM6). 22.4 mg dsHM6 were dissolved in 164.6 
µl PBS and mixed with 35.4 µl RGD solution. For the cell containing upper layer, 50 µl of the 
dsHM6 solution were mixed with 100 µl cell suspension (cells were suspended in fetal bovine serum 
(FBS)-free medium, cell concentration was 6 million/ml). For the fluorescently labeled and growth 
factor-free layers, 100 µl were mixed with 200 µl PBS. To the remaining 50 µl were added 7.5 µl of 
a 1 µg/µl PDGF-BB (Peprotech, Germany) solution and 92.5 µl PBS. The PEG solution was 
prepared by dissolving 30 mg PEG-MMP in 200 µl. 50 µl were combined with 100 µl cell 
suspension (in FBS-free medium, cell concentration was 4 million/ml) which was used for the cell 
containing layer. The fluorescently labeled precursor solution was prepared by mixing 50 µl of the 
PEG solution with 1.5 µl Atto647-maleimide solution and 98.5 µl PBS. For the PDGF-containing 
or -free bottom layer the remaining 100 µl were mixed with 200 µl PBS. After the preparation, the 
pH of the non-cell containing polymer solutions was adjusted to about 7.2. 
 
3.3 hMSC-laden hydrogels for chondrogenic 
differentiation 
3.3.1 Culture of human mesenchymal stromal cells 
Human bone marrow-derived mesenchymal stromal cells (hMSC) were provided as passage 1 cells 
by the University Hospital Carl Gustav Carus of the Technische Universität Dresden. The donors 
were male with an age range from 20 - 40 years.  
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After thawing, the cells were cultured in DMEM high glucose + pyruvate supplemented with 10% 
FBS and 1% penicillin/streptomycin (P/S) under a humidified atmosphere containing 5% CO2 at 
37°C. This medium composition is referred to as MSC growth medium. In later passages, the MSC 
growth medium was further supplemented by 5 ng/ml fibroblast growth factor 2 (FGF-2). The 
medium was changed every 2-3 days. Cells were cultured up to passage 3 before being used for 
experiments. 
In order to detach the cells for passaging or harvesting, the medium was removed, and the cells 
were washed twice with PBS. Subsequent incubation with a Trypsin/EDTA (ethylenediamine-
tetraacetic acid) solution for 2 min at 37°C detached the cells. Following addition of MSC medium 
stopped the enzymatic reaction. After centrifugation at 1300 rpm for 5 min, the medium 
supernatant was removed, and the cells were resuspended in the desired medium for later 
experiments. Then the cells were counted with a CASY® 1 Model TT cell counter (Scharf Systems, 
Germany). After another centrifugation and resuspension step the cells have been ready to be used 
for gel embedding or printing. 
 
3.3.2 Preparation of hMSC-laden hydrogels for chondrogenic 
differentiation of hMSC  
The gel type for chondrogenic differentiation experiments of hMSC was a 75% MMP-cleavable 
PEG-heparin gel with 1 mol RGD per 1 mol heparin and a γ = 1.5. The cell concentration was set 
to 20 million/ml. Furthermore, a TGF-ß1 preloading (200 ng/ml) was applied to facilitate cell 
differentiation from the start and to prevent any possible growth factor diffusion problems due to 
the high binding affinity and capacity of heparin in the first days of culture. These hydrogel 
parameters were defined as standard condition for the chondrogenic differentiation. 
For the preparation of 200 µl hydrogel volume, 100 µl of the precursor solutions were prepared. 
4.48 mg HM6 were dissolved in 26.53 µl PBS, mixed with 6 µl RGD and supplemented with 0.8 µl 
of a 50 ng/µl TGF-ß1 solution. Then 66.6 µl cell suspension were added and gently mixed (cell 
concentration was 60 million/ml, cells were suspended in chondrogenic differentiation medium, 
consisting of DMEM high glucose + pyruvate supplemented with 1% P/S, 1% amphotericin B, 
1% insulin/transferrin/selenious acid + premix (Corning, Deutschland), 2 µg/ml dexamethasone, 
58 µg/ml ascorbic acid 2-phosphate and 10 ng/ml TGF-ß1). The PEG solution was prepared by 
combining 2.4 mg PEG-SH in 50 µl PBS with 10.4 mg PEG-MMP in 50 µl PBS. Subsequently the 
pH of the PEG solution was adjusted that the gelation time was about 30-40 sec. Then 25 µl 
hydrogel droplets were casted on glass coverslips coated with Sigmacote® (Sigma Aldrich, 
Germany) (5 mm diameter) by mixing 12.5 µl of each polymer solution for 15-20 sec. The hydrogels 
were left to polymerize for 5 min under a humidified atmosphere and then immersed into 1 ml 
chondrogenic differentiation medium in a 24 well plate. The culture period was 6 weeks with 
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medium changes every 2-3 days. Thereafter the gels were harvested by washing them twice with 
PBS for 5 mins, then fixation in 4% paraformaldehyde (PFA) for 10 min (for immunostaining) or 
they were directly frozen at -80°C (for mechanical testing).  
 
3.3.3 Variation of hydrogel parameters  
Due to the modular nature of the hydrogel system, there was the possibility to vary several hydrogel 
parameters. 
A different crosslinking degree was achieved by altering the molar ratios (γ) of PEG to HM6. 
In order to isolate the influence of different crosslinking degrees and with it a different gel stiffness, 
the concentration of heparin as the primary bioactive component was kept constant. The PEG 
concentration was therefore adjusted to prepare hydrogels with a γ between 0.5 and 1.5. 
Hydrogels with different MMP-degradability were prepared by adjusting the molar ratio 
between PEG-SH and PEG-MMP. Fully MMP-degradable (only PEG-MMP as PEG component) 
and non-degradable (only PEG-SH) hydrogels as well as intermediate degradable gels with a mixed 
PEG composition were prepared and tested. The PEG-MMP content in relation to the overall 
thiol group-bearing PEG content was varied from 75% to 60%, 40%, 20% and 0% while the PEG-
SH content was inversely increased. 
Gels with varying heparin content were prepared by substituting HM6 with maleimide-
functionalized 4-arm PEG (PEG-MAL) while maintaining the solid content at 5.2% (standard 
heparin hydrogel). The heparin content was gradually reduced to 50%, 10%, 1% and finally 0% 
(which was considered as a pure PEG gel) of the original concentration by combining solutions of 
HM6 and PEG-Mal with appropriate polymer contents. 
 
3.3.4 Further adjustments to influence chondrogenic 
differentiation 
Growth factor combinations 
IGF-1 (Peprotech, Germany) preloading and BMP-7 (Peprotech, Germany) supplementation were 
used for multi-growth factor induced and enhanced chondrogenic differentiation of hMSC. For 
IGF-1 treatment, the growth factor was preloaded into the hydrogel with a concentration of 600 
ng/ml. BMP-7 was supplemented into the medium at a concentration of 100 ng/ml over the whole 
culture period of 6 weeks. 




The chondrogenic differentiation medium was supplemented with polyvinylpyrrolidone (PVP, 40 
kDa, Sigma Aldrich, Germany) as the macromolecular crowder. Different crowder concentrations 
were used to arrive at fractional volume occupancies (FVO) of 9%, 18% and 36% which would 
translate into 10.8, 21.6 and 43.2 mg per ml medium, respectively. To calculate the mass 
concentrations, the dissolved crowder molecule was considered as idealized sphere having a 
hydrodynamic radius of 5.1 nm and a molecular mass of 40000 g/mol. The crowder was added 
over the whole culture period.  
 
3.4 Analysis of casted and printed hydrogels 
3.4.1 Live/dead staining  
Printed hydrogels on coverslips were washed twice with PBS and incubated with 4 mM calcein-
AM (Merck, Germany) and 1.5 mM propidium iodide (Sigma-Aldrich, Germany) for 20 min at 
37°C for staining live and dead cells, respectively. Subsequently the cells were imaged with a 
widefield microscope Axio Observer (Zeiss, Germany). 
 
3.4.2 Live cell imaging  
For visualizing cells while keeping them alive for later imaging sessions, the cell-containing 
hydrogels scaffolds were incubated with non-cytotoxic 4 mM calcein-AM for 15 min at 37°C. 
Subsequently the hydrogel-bearing coverslips were transferred into sterilized Nunc™ glass bottom 
dishes (Thermo Scientific, Germany) and imaged with a confocal microscope TCS SP5 (Leica, 
Germany). After the imaging was finished, the samples were immersed back into the appropriate 
medium for the continuing culture. 
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3.5 Analysis of the chondrogenic differentiation 
3.5.1 Immunohistochemistry 
Prior to the immunostaining, the samples had to be cut into thin sections. Therefore, the frozen 
PFA fixed samples were firstly thawed, then embedded into Tissue-Tek® optimum cutting 
temperature compound (OCT) (Sakura Finetek, USA) and lastly frozen on dry ice. Subsequently 
the embedded samples were cut into 16 µm thick sections with a cryostat microtome (sample and 
blade temperature both at -17°C) and attached onto Superfrost Plus™ microscope slides (Thermo 
Scientific, USA). 
After thawing the slides in a staining chamber, the sample sections on the slides were circled with 
a liquid blocker pen and washed twice with PBS to wash away the OCT. Then an antigen retrieval 
step was performed with 0.5 mg/ml pepsin (in 0.01 M HCl) for 10 min at 37°C. The samples were 
washed twice with PBS and then blocked with blocking buffer (5% serum of the host of the 
secondary antibody in PBS) for 1h at room temperature. Subsequently the primary antibody for 
the required ECM molecule diluted in washing buffer (20% of the blocking buffer in PBS) was 
added for incubation overnight at 4°C. The following primary antibodies were used: anti-collagen 
type II (mouse, 5 µg/ml, MP Biomedicals, USA), anti-collagen type I (mouse, 5 µg/ml, Merck, 
Germany), anti-collagen type X (mouse, 10 µg/ml, Invitrogen/Thermo Fisher, Germany) and anti-
lubricin (mouse, 1 µg/ml, Merck, Germany). Then the samples were washed 3x for 15 min with 
washing buffer and incubated with the secondary antibody (anti-mouse Atto 532, goat, 10 µg/ml, 
Invitrogen/Thermo Fisher, Germany) diluted in washing buffer for 1h at room temperature. After 
a further washing step (3x for 15 min with washing buffer) the samples were incubated with 5 
µg/ml Hoechst 33342 in PBS for 10 min at room temperature, then washed twice with PBS and 
mounted for sample preservation. Eventually the slides were used for fluorescence microscopy or 
stored at -20°C. The samples were imaged with a confocal microscope TCS SP5. In order to 
compare and analyze the fluorescent intensity of the stained ECM components, all samples were 
imaged with the same settings concerning laser intensity (10% argon laser intensity, 5% 514 nm 
excitation laser) and detector sensitivity (100% of the HYD detector).  
 
3.5.2 Toluidine blue staining  
In order to visualize sulfated GAGs, a toluidine blue staining was applied. Thin sections of the 
hydrogel samples (prepared as described above) were incubated with a 0.1% toluidine blue solution 
(dissolved in PBS) for 30 sec at room temperature. Subsequently, the samples were washed 3x with 
PBS, mounted and imaged with bright-field microscopy. 
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3.5.3 AFM nanoindentation 
The micromechanical properties of samples were determined by AFM-based nanoindentation 
experiments. One to two-millimeter-thick slices were cut from the central part of the samples using 
a razor blade. The slices were immobilized to polyethyleneimine-coated petri dishes (Ø 3cm, TPP). 
Samples were fully immersed in PBS during the measurements. A NanoWizard IV AFM (JPK 
Instruments, Germany) mounted on an Axio Observer D.1 (Zeiss, Germany) was used to perform 
nanoindentation experiments. Measurements were conducted at 25°C using a PetriDishHeater™ 
(JPK Instruments, Germany) sample chamber. Tipless silicon nitride cantilever with a nominal 
spring constant of 80 mN m-1 (PNP-TR-TL-Au; Nanoworld) were used. Cantilevers were 
modified with silica beads (∅10 mm, Kisker Biotec GmbH, Germany) as previously described.[214] 
Spring constants were calibrated before measurements using the equipartition theorem.[215] For 
nanoindentation measurements, the approach and retract velocity was set to 5 µm s-1, the contact 
force to 4 nN, and the pulling range was 20 µm. Experiments were performed in closed-loop, 
constant height mode. Each data set was generated by recording 3 – 4 force maps (25 spots, 100 x 
100 µm2) in separate areas of the sample slice. The data processing software provided by the AFM 
manufacturer (JPK Instruments, Germany) was used to extract the Young’s Modulus E from 
approach force-distance curves. 
 
3.5.4 Total collagen assay 
For collagen quantification, a hydroxyproline (HP) assay kit was used (Sigma Aldrich, Germany). 
The assay was performed according to the manufacturer’s protocol. Briefly, the hydrogel and 
micromass culture samples (with and without PFA fixation) were hydrolyzed with 6 M HCl at 
120°C in a pressure-tight glass container overnight. After cooling down the samples were dried 
under vacuum, then resuspended in an appropriate volume of MilliQ water (about 12 µl per mg 
hydrogel and 50 µl per mg micromass culture) and centrifuged after 1h. 10 µl of the supernatants 
were transferred into a 96 well plate, dried at 60°C and then oxidized with a Chloramine T solution 
for 5 min at room temperature followed by incubation with a 4-(dimethylamino)benzaldehyde 
(DMAB) solution for 90 min at 60°C (both chemicals were part of the kit). The resulting 
chromophore absorbance was measured at 560 nm with a Tecan reader Spark 10 M (Tecan, 
Germany). The collagen contents were calculated by determining the absolute HP contents from 
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3.6 Statistical and image analysis 
All quantitative data was analyzed and presented by GraphPad Prism 6 (GraphPad Software Inc., 
USA). Statistical significance between the samples was determined by applying one-way ANOVA 
with Tukey post-hoc test. Asterisks representing level of significance were defined as: * = p<0.05; 
** = p<0.01; *** = p<0.001; **** = p<0.0001.   


















4 Results and Discussion
4.1 Bioprinting of cell-laden hydrogel scaffolds 
The first objective of this thesis was to establish standard operating procedures to print hMSC-
laden dual component hydrogels with zonal architectures having layer resolutions in the range of 
articular cartilage by using the inkjet printer Nanoplotter 2.1™. It was intended to investigate the 
printability of hMSCs and other cell types, upper limits of printable cell concentrations and to 
evaluate the cell viability after printing to test for possibly negative influences of the printing 
process on the cells. Furthermore, the maintenance of the cellular functionality should be 
demonstrated with a cell migration experiment as a specific application of the 3D bioprinted 
constructs. The starting point were procedures and protocols towards inkjet printing of starPEG-
heparin hydrogels developed by former bachelor student Christoph Hentschel, on which this part 
of the thesis continued to build on.  
 
4.1.1 Printing of structured hydrogels 
To investigate the possibilities of inkjet printing to fabricate hydrogels with different structural 
dimensions, the first aim was to print a variety of horizontally and vertically structured hydrogels. 
Fluorescent labeling via covalent attachment of maleimide-functionalized Atto dyes to the thiolated 
starPEG component was applied in order to visualize the printed structures with fluorescent 
microscopy. A hexagonal plotting pattern defining the arrangement of the spots in a hexagonal 
lattice structure was selected using a setting of 3 droplets per spot. The hexagonal lattice was chosen 
since it packs spheres with the highest density leading to a fully annealed hydrogel layer made of 
theoretically spherical hydrogel droplets (Figure 8). The stroboscope test showed that each droplet 
from the polymer solutions had a volume of approximately 700 pl. Due to the droplet-based 
material deposition principal, the distance between the printing spots on which the printer was 
plotting the dual-component hydrogel precursor solutions was required to be small enough in order 
to fuse the droplets to a closed hydrogel layer. A homogenous droplet fusing only occurs when the 
spot distance is smaller than the spreading radius of the plotted hydrogel droplets which in turn 
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depends on the surface characteristics of the underlying substrate. Poly(ethylene-alt-maleimide 
anhydride) (PEMA)-coated glass coverslides functionalized with N-(2-aminoethyl)maleimide were 
used as substrates in order to covalently immobilize the printed hydrogels. It has been shown by 
Pompe et al. that PEMA-coated glass surfaces have a water contact angle of about 57°.[217] Since 
every printed hydrogel droplet consisted of 2 x 3 droplets with 700 pl each resulting in 4,2 nl 
hydrogel per spot, the hydrogel would theoretically cover an area with a radius of about 165 µm on 
the PEMA-glass surfaces. Therefore, the applied spot distance of 144 µm in the hexagonal lattice 
was considered as appropriate while simultaneously avoiding unwanted, local piling up problems 
of the printed hydrogels. To test these calculated values, a hydrogel array with higher spot distances 
was printed. The evaluation of the fluorescent microscopy images showed an average diameter of 
the printed hydrogel droplets of 185 µm which was in the range of the theoretical values and also 
demonstrated the high precision of the deposited material. 
Figure 8 – Schemata of the hexagonal spot pattern (A) and the lateral view of the theoretical droplet overlap 
to form cohesive hydrogel layers (B). Fluorescent microscopy images of printed hydrogel droplets consisting 
of 3 droplets per spot with a spacing of 800 µm on a PEMA-coated glass substrate. Scale bar: 500 µm (C). 
With these established printing parameters, a variety of horizontally and vertically structured 
hydrogel scaffolds were printed in order to confirm the feasibility of this printing technique. The 
printed hydrogels were composed of either starPEG-heparin or pure starPEG hydrogels, both 
being dual component hydrogels using a Michael-type addition thiol-maleimide crosslinking 
reaction scheme. It was crucial to adjust the pH of the maleimide- and thiol-containing solutions 
to about 7.2 to achieve a fast reaction time. This was necessary to quickly solidify the plotted gel 
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to form instability resulting in heterogeneous hydrogel surface patterns and uncontrolled local 
gelation. The constructs had a variable size but where usually printed with a lateral dimension of 
5x5 mm2 and a height of up to several mm depending on the number of deposited layers. The 
printing time for one homogeneous layer was about 5 mins while horizontally structured layers 
(Figure 9B) would take significantly longer due to interim changes of the printing solutions and 
pipette washing steps. For vertically structured, layered hydrogels, the layer thickness could be 
adjusted by changing the number of droplets per spot. A layer thickness of 50 µm could be achieved 
with a 1 droplet per spot setting. This is at the lower limit of what inkjet-based printing systems 
generally can achieve.[218]  
Figure 9 – Fluorescent (left) and bright field (right) images of printed hydrogel scaffolds. Lateral view on a 
triple-layered starPEG-heparin hydrogel with fluorescently labeled bottom- and top layer and non-
fluorescent middle layer (A). Top view of a stripe-structured and fluorescently labeled hydrogel construct 
composed of starPEG-heparin (red) and pure starPEG (green) (B). Scale bar: 1 mm. 
In addition, the spatial resolution was dependent of the viscosity of the polymer solutions. A higher 
applied voltage of the piezoelectric actuators was necessary to eject more viscous solutions which 
would lead to larger droplets. Therefore, the resolution was also a function of the polymer 
concentration. An upper limit for the polymer concentration was found to be around 6-7% (w/v) 
due to arising clocking issues with the pipettes at higher concentrations, while the lower limit was 
A 
B 
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around 2.5% to arrive at a polymer overlapping concentration being necessary for the general 
hydrogel formation. Usually a polymer concentration of 4-5% was applied for printed hydrogels. 
The starPEG solutions generally generated more clocking problems due to a higher intrinsic 
viscosity than the heparin solution and the possibility of forming in situ hydrogel networks via 
disulfide formation of the thiol groups. This is considered to also explain the increasing problems 
with pipette clocking over the printing time. Generally, 4-5 hours after the initial preparation of the 
printing solutions, the frequency of clocking issues demanded the preparation of fresh gel 
precursor solutions or the exchange of the pipettes in case the clocking originated from hydrogel 
formation at the nozzle due to unintended liquid spraying of the other blocked pipette.  
The presented examples demonstrate the feasibility of printing dual component heparin- and PEG-
based hydrogels with a Michael-type addition crosslinking scheme to fabricate structurally complex 
hydrogel constructs with controllable spatial resolution. Hence, these findings were used in the 
next stage to develop procedures for printing cell-laden hydrogel scaffolds. 
 
4.1.2 Printing of cell-laden hydrogels 
Printing of cells embedded in hydrogels or from suspension in scaffold-free approaches has been 
reported for a variety of bioprinting techniques including inkjet, extrusion and laser-based printing. 
While extrusion bioprinting has the advantage to print significantly higher cell concentrations than 
inkjet printing (generally < 10 million cells per ml), the latter can achieve higher material deposition 
resolutions. The results of the former section showed the successful preparation of layered 
hydrogels with high spatial resolution in the z-axes. This could be particularly interesting for 
cartilage tissue engineering. To replicate the zonal architecture of articular cartilage, a layer-by-layer 
deposition method would be a promising approach.[11] In order to test the printability of cell-laden 
hydrogels, first printing trials were performed using mouse fibroblasts of the cell line L929. These 
cells were chosen due to their fast 2D expansion behavior and their relatively high resistance 
towards chemical and mechanical stress. Furthermore, it is reported that the deposition of L929 
cells with piezoelectric inkjet printing has no negative influence on the cell viability.[219] Therefore, 
any impairment on the cell viability would indicate too much stress exercised on the cells. The 
analysis of the resulting constructs showed a high cell viability directly after printing and a strong 
cell proliferation in the next 7 consecutive days (data not shown).  
Subsequently, more sophisticated approaches were initiated using hMSCs to be printed in starPEG-
heparin hydrogels. The first attempts yielded hydrogels with a significantly lower cell concentration 
than calculated. Furthermore, it could be observed that the cell density in the printed constructs 
decreased over time eventually leading to cell-free hydrogels after a certain period of time. A careful 
investigation revealed that most of the initially suspended cells settled at the well plate bottom over 
time and the printing pipettes which were freshly loaded with the gel precursor solutions before 
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every printing step did not take up the cells. Extensive, but careful mixing of the cell-laden polymer 
solutions prior to the aspiration step eventually solved this problem in later experiments. However, 
it was observed that despite careful resuspension efforts pipette clocking issues started to become 
more frequent over time when MSCs were printed. The in-situ formation of MSC aggregates 
mediated by cadherin-cadherin interactions was considered to be the reason for that problem.[220] 
The average diameter of hMSCs is about 25 µm[221] which is significantly below the nozzle diameter 
of 55 µm and therefore, freshly and homogeneously suspended cells were able to pass the outlet 
without generating clocking problems. Due to the aggregation over time, cell spheroids can grow 
into dimensions well over 100 µm which would result in blocked pipette outlets. It has been 
reported that ethylenediaminetetraacetic acid (EDTA) can disturb the MSC aggregation at higher 
concentrations by chelating calcium cations which are important for the functionality of E-
cadherin.[222] However, it was decided to not use EDTA in order to avoid any unintended cell 
adhesion problems to the hydrogel after the printing. Hence, the preparation of fresh cell-
containing polymer solutions was the only option once cell aggregation-induced clocking problems 
started to hinder the printing process. 
The viability of printed hMSCs in MMP-degradable starPEG-heparin hydrogels was evaluated for 
different cell concentrations for up to one week in culture. When a relatively low cell concentration 
(1 million cells per ml) was printed, the viability was almost 100% directly after printing. After 7 
days in culture, 90% of the cells were still alive. For high cell concentrations (5 million cells per 
ml), the initial viability was 85%, then dropped to 80% after 3 days and remained at this level for 
the next 4 consecutive days (Figure 10B). This data is in line with reported values of printed MSC-
laden hydrogel constructs using inkjet bioprinting methods.[223] It could be observed that the cells 
started to spread in the hydrogel after several days in culture, particularly at the gel periphery. Cell 
spreading is a well-known behavior of MSC’s on surfaces and in 3D environments.[224] The 
spreading at the gel edges could be explained by a smaller gel thickness at the periphery which 
would lead to cell attachment on the underlying PEMA-coated glass coverslide after enzymatically 
induced gel degradation over time. The spreading was also observable in the 3D bulk gel but to a 
lesser extent. In order to correctly quantify the number of live and dead cells, the cell nuclei had to 
be counterstained with Hoechst 33342 since the spreading made it impossible to distinguish the 
calcein-stained cells due to the formation of small interconnected cell networks after 7 days in 
culture. The analysis of the total number of nuclei over the whole culture period revealed no 
noticeable increase in cell number despite being cultured in MSC growth medium which is generally 
applied in 2D expansion cultures.  
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Figure 10 – Top view of fluorescent images of printed, double layered (~250 µm thick) hMSC-laden, 75% 
MMP-degradable starPEG-heparin hydrogels (5 million cells per ml) stained with calcein (green) and 
propidium iodide (PI, red) for live/dead staining directly after printing (day 0) and after 7 days in culture. 
Scale bar: 1 mm (A). Quantification of live and dead cells via combination of counting calcein and PI-stained 
cells and Hoechst 33342 counterstained nuclei (not shown) for total cell number determination (mean ± 
s.d., n = 3 per time point) (B). 
In the next step, hMSC-laden hydrogels with increasing cell concentrations were printed in order 
to find the upper limit for the inkjet printer. As expected, the higher the tested cell concentration, 
the more problems with pipette clocking occurred. After several trial-and-error experiments, an 
upper limit for hMSCs was found to be at 8 million cells per ml. The heparin solution was loaded 
with 10 million cells per ml while the PEG solution with 6 million per ml. Higher cell 
concentrations in both solutions proved to be unprintable from the start. However, even the 8 
million cells per ml concentration remained printable only for a relatively short amount of time due 
to a fast formation of cell aggregates despite extensive efforts for resuspension and mixing prior to 
the aspiration step. Therefore, a practically printable cell concentration of 5-6 million per ml was 
Day 0 Day 7 A 
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chosen for longer printing periods. Besides the cell concentration, the cell type also had an 
influence on the viscosity and therefore printability of cell-laden hydrogels. Printing of porcine 
chondrocytes with cell concentrations of up to 15 million cells per ml was possible, most likely due 
to a smaller cell dimension and a lower aggregation tendency of these cells. Furthermore, iPSCs 
printability was shown by printing onto a Matrigel-coated well resulting in patterned cell 
attachments with high viability (Figure 11).  
Figure 11 – Top view of fluorescent microscopy image of a single layered porcine chondrocytes-laden 
starPEG-heparin hydrogel with a cell concentration of 15 million cells per ml visualized with live/dead 
staining (A). Printed iPSC into a 6 well plate coated with Matrigel. Cells were stained with calcein (B). Scale 
bar: 1 mm. 
In order to investigate the influence of suspended cells in the gel precursor solutions on the lateral 
printing resolution, layered hMSC-laden hydrogels with different cell concentrations were printed 
(Figure 12B). The analysis of the fluorescent microscopy images showed a more uneven hydrogel 
layer geometry when the gel was printed onto an underlying, cell-laden hydrogel layer. This could 
be explained by a lower control of the droplet shape and size observed in the stroboscope test 
when cell-containing polymer solutions were plotted. Furthermore, a higher voltage at the 
piezoelectric actuators was necessary to eject the droplets due to a higher, cell-concentration 
depending viscosity of the precursor solutions resulting in generally larger liquid droplets. Due to 
the very fast crosslinking reaction once the gel precursor droplets fused upon contact on the 
substrate, the more viscous liquid droplets could probably not spread as fast and even as the cell-
free polymer solutions leading eventually to slightly more heterogeneous and rougher hydrogel 
surfaces.  
A B 
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Figure 12 – Lateral view of layered, hMSC-laden hydrogel constructs. Bright field (top) and live/dead 
fluorescent microscopy (bottom) image of triple layered hydrogel with cell-free, non-fluorescent top and 
bottom layer and cell-containing middle layer (3 million cells per ml) (A). Fluorescent microscopy image of 
multilayered hydrogel scaffold having 3 distinct cell-containing layers with different cell concentrations 
ranging from 2 (top), 5 (middle) to 8 (bottom) million cells per ml, separated by red fluorescent, cell-free 
hydrogel layers, cell nuclei were stained with Hoechst 33342 (B). Scale bar: 1 mm. 
Despite optimization efforts including variation of the applied voltage and testing pipettes with 
different batch numbers, the spatial resolution was primarily a function of the cell concentration 
with an inverse proportional relation. However, the layer thicknesses of the printed cell-laden 
constructs were well in the range of articular cartilage layer dimensions where the superficial zone 
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4.1.3 hMSC migration assay in printed starPEG-heparin gels 
After it was demonstrated in the former section that dual component hydrogel inkjet bioprinting 
with the Nanoplotter 2.1™ could be used to fabricate cell-laden hydrogel scaffolds exhibiting high 
post-printing viability for different cell types and cell concentrations combined with the possibility 
of horizontally and vertically structured hydrogel arrangements with high resolution, the further 
emphasis was to investigate the functionality of such a printed construct. As a proof-of-concept 
application, a chemotactic MSC migration experiment was designed. A triple-layered hydrogel was 
fabricated having a cell-containing top layer which was separated by a fluorescently labeled, cell- 
and growth factor-free middle “separation” layer from the underlying, dimeric platelet derived 
growth factor B (PDGF-BB)-containing bottom layer being the pool of the cell-attracting growth 
factor (Figure 13B). PDGF-BB was chosen for two reasons. Firstly, it is a well-known and applied 
chemoattractant for a variety of cells including MSC’s in vitro and in vivo.[225,226] And secondly, heparin 
strongly binds and stabilizes PDGF-BB which is used in growth factor delivery systems.[227] This 
property was particularly important since the hydrogel construct was cultured in serum- and growth 
factor-free medium to avoid unintended hydrogel binding site saturation with serum-originating 
growth factors which would disturb or even possibly neutralize the chemoattractive effect of the 
forming PDGF-BB gradient. Therefore, a low binding hydrogel would lead to a fast diffusion of 
the loaded growth factor into the medium and a quick homogenization inside the hydrogel which 
would prevent the necessary gradient formation for cell migration. Besides being a visual 
benchmark, the 50 µm thick middle layer also served as gradient forming layer. The hydrogel was 
chosen to be cell adhesive via RGD functionalization (1 mol RGD per mol heparin) and fully MMP 
degradable indicated by 3D heparin immobilization with starPEG-MMP crosslinkers to allow cell 
migration through the hydrogel via MMP-induced gel degradation. In order to visualize the 
migrated cells, calcein staining was performed prior to each measurement time point which was 
every 7 days for 4 weeks. Calcein has the advantage of visualizing the whole morphology of the 
living cells while being completely non-cytotoxic. This was particularly important since the live 
imaged cells were kept in culture for the full time period.  
Initial experiments were carried out with a culture period of 3 weeks. However, there was no 
difference in the cellular distribution over the gel layers observable compared to the PDGF-BB-
free control after the whole culture period. It was hypothesized that despite a relatively high growth 
factor concentration in the bottom layer (50 ng/µl) the electrostatic binding to the heparin was too 
strong to form a PDGF-BB gradient in the z-direction. Therefore, a selectively 6O,N-desulfated 
heparin with a significantly lower content of sulfate groups was used. It has been previously shown 
by our group that heparin desulfation results in a lower growth factor binding capacity for a broad 
range of growth factors including PDGF-BB.[228] Furthermore, the culture time was increased to 4 
weeks to observe longer term effects of the gradient formation on the printed cells compared to 
control gels. The results for the experiment using desulfated heparin are shown in Figure 13. 
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Figure 13 – PDGF-BB induced hMSC migration in printed 100% MMP-degradable starPEG-6ON 
desulfated heparin hydrogels, γ = 1.5, modified with 1 mol RGD per 1 mol heparin. Fluorescent confocal 
microscopy images of growth-factor loaded and control hydrogels at day 1 and day 29, cells were stained 
with calcein for live cell imaging, shown are the maximal z-projections of 50 µm and 110 µm sections of the 
separation layer and the top or bottom layer, respectively. Scale bar: 200 µm (A). The scheme of the three-
layered hydrogel construct with a PDGF-BB loaded bottom layer, fluorescently labeled separation layer and 
hMSC-containing top layer, the grey dotted line indicates the transition from the top to the bottom half of 
the construct (B). Quantification of the cell migration by determining the fraction of total fluorescence of 
Calcein-stained hMSCs in the bottom half of the constructs for PDGF-BB loaded and control hydrogels 
for day 1, 8, 15, 22 and 29 after printing (mean ± s.d., n = 2-3 per condition) (C). 
A significant difference in hMSC distribution over the hydrogel could be observed in the PDGF-
BB-loaded constructs after 4 weeks in culture while the growth factor-free control showed only 
minor migration tendencies in the first week followed by a dropping cell number in the following 
21 days (for more information, see appendix). Furthermore, cell spreading was observable for both 
conditions after 1 week. In case of the PDGF-BB-loaded condition, the spreading became more 
pronounced over time, particularly for migrated and proliferated cells in the bottom growth factor 
reservoir layer. In contrast, the cells in the control gel showed reduced spreading in the last 3 weeks. 
The quantification of the confocal microscopy data showed the occurrence of the first significant 
difference in the number of migrated cells measured by the share of the fluorescence of the stained 
cells in the bottom half relative to the total fluorescence after 15 days in culture. This difference 
between the PDGF-BB-loaded and the control hydrogel was growing until the end of the culture 
period of 4 weeks. At day 29, about 60% of the total fluorescent signal intensity could be detected 
in the bottom half of the construct indicating an almost uniform cell distribution. It must be 
mentioned that the observed migration could also be the result of a directed cell proliferation along 
the z-axis towards the growth factor reservoir. In a purely migratory setting, the total cell number 
would stay the same while only the cell distribution would change. Due to the earlier mentioned 
problems to distinguish spreaded, calcein-stained cells for proper cell number quantification, low 
cytotoxic Hoechst 33342 nuclei stain was added to the staining protocol to investigate any changes 
in cell number. However, it was observed that the DNA staining had a negative impact on the cells 
over the culture period indicated by a significantly lower cell spreading and migration behavior. 
Therefore, the demonstrated PDGF-BB-induced migration is thought to be a combination of cell 
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4.1.4 Summary and Conclusion 
The results of this first part of the thesis demonstrated the successful development of protocols 
and procedures to print dual component starPEG-heparin and pure PEG hydrogels with the inkjet 
printing method. Zonal hydrogel scaffolds with variable layer thicknesses were able to be fabricated 
with high reproducibility. Printing of cells from different sources, types and at different 
concentrations into cell-laden hydrogel scaffolds proved to have no negative influence on the 
cellular viability indicated by >80 % live cells directly post-printing and after 7 days in culture. 
Finally, the functionality of the printed cells and the produced hydrogel architecture was 
demonstrated by a successful PDGF-BB-induced hMSC migration assay in a multilayered hydrogel 
construct which resulted in a nearly uniform distribution of highly spreaded cells after 4 weeks in 
culture compared with a significantly lower cell migration in growth factor-free controls.  
A general drawback were the pipette clocking issues at higher cell concentrations, particularly for 
hMSCs due to cell aggregation and an increasing viscosity over time. The maximally printable 
hMSC concentration of 8 million cells per ml was in the range of published values. However, a 
concentration of 5-6 million cells per ml was used as applicable concentration in cell-laden 
constructs due to a significantly reduced risk of blocked pipettes, particularly in the later stages of 
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4.2 3D cell culture and chondrogenic 
differentiation of hMSCs in the starPEG-
heparin hydrogel 
The primary objective of the second part was to investigate the chondrogenic differentiation of 
hMSCs in printed starPEG-heparin hydrogels and their relative performance compared to casted 
control gels. A further emphasis was the induction of hMSC proliferation in the 3D bulk hydrogel 
to increase the local 3D cell density in-situ to counteract the limited printable hMSC concentration 
for an enhanced chondrogenic potential of printed hydrogels. 
 
4.2.1 3D hMSC cell culture in starPEG-heparin hydrogels 
With regards to the impaired possibility of printing high hMSC cell densities, a cell proliferation 
step in the 3D culture was considered as a possible option prior to the induction of the 
chondrogenesis. It was reported that high cell concentrations are crucial for chondrogenic 
differentiation of MSCs in 3D culture.[229,230] These findings go along with the requirement for 
mesenchymal condensation as important initiation step in the embryogenic chondrogenesis 
pathway. Therefore, the rational was to print the maximally achievable but probably not ideal 
hMSC concentration which should be further increased by stimulating the 3D proliferation of post-
printed MSCs. Once the cell density should have reached a desired level, the chondrogenic 
differentiation would be initiated by changing to a chondroinductive medium. 
Hence it was necessary to study the proliferative potential of hMSCs in 3D starPEG-heparin 
hydrogel cultures. As it has been shown in the former section, the cell number of printed MSCs 
cultured with MSC expansion medium containing 10% FBS did not increase after 1 week despite 
a high cell viability. Therefore, the use of FGF-2 with different concentrations and an increase of 
the FBS content to 20% were hypothesized to stimulate the 3D cell proliferation. FGF-2 has been 
reported to be the most efficient growth factor for the stimulation of MSC growth and acting as 
an enhancer of the chondrogenic potential in vitro.[231–234] Furthermore, FGF-2 binds strongly to and 
is stabilized by heparin, and shows prolonged and enhanced bioactivity in this complexed 
form.[235,236] The proliferation experiments were performed for 2 weeks in casted fully MMP-
degradable hydrogels modified with RGD. The casted version was chosen due an easier and faster 
production of a sufficient amount of gel samples for statistic relevance compared to the difficulty 
of printing higher quantities of hydrogel constructs with a comparable size. RGD functionalization 
and MMP degradability were intended to provide a biomimetic cell environment to further facilitate 
cell attachment and division. The results of the calcein-stained samples for every time point and 
condition are presented in Figure 14. 
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Figure 14 – 3D cell culture experiments of hMSCs in starPEG-heparin hydrogels under different medium 
conditions. Fluorescent confocal images (maximal z-projections of 200 µm thick sections) of calcein-stained 
hMSCs in the bulk hydrogel (100% MMP-degradable, γ = 1.5, modified with RGD) after 1, 7 and 14 days 
in culture, medium compositions were altered in FBS content (10% and 20%) and FGF-2 concentration (0, 
1, 10 and 50 ng/ml) to induce 3D cell proliferation. Scale bar: 200 µm (A). Quantification of the relative 
change in 3D cell concentration over the culture period (mean ± s.d., n = 3 per condition) (B). 
The quantification of stained cells showed no signification increase of the cell number for all tested 
conditions after 14 days in culture (Figure 14B). Instead, a decrease in the quantity of live cells 
could be observed for almost all conditions. The best condition was using the highest FGF-2 
concentration in medium (50 µg/ml) with 10% FBS supplementation which showed an overall 
slight increase in 3D cell number. Furthermore, it was observed that only this condition triggered 
cell spreading after the full culture period. For the other conditions, cells maintained their round 
morphology and no difference was observable when samples of day 1 and 14 were compared 
(Figure 14A). Mimura et al. reported enhanced MSC proliferation in vitro when supplemented with 
FGF-2 and soluble heparin.[231] However, this could not be observed in the performed experiments, 
probably due to different experimental settings (3D vs. 2D MSC cell culture). Furthermore, the 
increase in FBS content to 20% did not prove to be beneficial and resulted in similar results like 
the 10% version. This led to the conclusion that external nutrient and biochemical stimuli supply 
due to possible diffusion problems inside the strongly growth factor and protein-binding heparin-
based hydrogel was unlikely to be the reason for the absence of cell growth. It was hypothesized 
that despite the incorporation of MMP-inducible gel degradation sites and RGD cell adhesion 
motifs, the gel network was too dense and stiff resulting from the high crosslinking degree. 
Therefore, the proliferation assay was tested in starPEG-heparin hydrogels with different 
crosslinking degrees with using the best tested medium composition containing 50 µg/ml FGF-2 
and 10% FBS. The results of this experiment are shown in Figure 15. 
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Figure 15 – 3D hMSC cell culture in 100% MMP-degradable, RGD-modified starPEG-heparin hydrogels 
with different crosslinking degrees (γ = 0.5, 1.0 and 1.5), cultured in medium supplemented with 10% FBS 
and 50 ng/ml FGF-2. Fluorescent images (max. z-projections of 200 µm thick sections) of calcein (green)- 
and Hoechst 33342 (blue)- stained cells, shown are the projections of the 3D bulk hydrogel for day 1, 7 and 
14 and projections including the  gel surface for day 14 to demonstrate 2D cell proliferation on the gel. Scale 
bar: 200 µm. (A). Quantitifaction of the relative change in 3D cell concentration for the different 
crosslinking degrees over the culture period of 14 days (mean ± s.d., n = 2-3 per condition) (B). 
The fluorescent images of the calcein-stained cells showed strong cell spreading in soft gels (γ = 
0.5) compared to slight indicators of spreading in stiffer gels. Due to this observation, the cells 
were also stained with Hoechst 33342 to quantify the cell number even in highly branched cell 
networks (Figure 15A, γ = 0.5 gel at day 14). Independent of the crosslinking degree, there was no 
increase in cell number observable in the 3D bulk gel after 2 weeks in culture (Figure 15B). Strong 
cell proliferation was detected only on the gel surface of the soft gels indicated by a higher calcein 
fluorescent signal intensity and a significantly higher number of cell nuclei. Surface proliferation 
was also observable on the stiffer hydrogel surfaces but to a minor extent. Interestingly, additional 
tests for metabolic activity using a Prestoblue™ assay delivered higher values for the soft gels which 
is an indicator for an increased number of cells (Data not shown). However, this assay takes into 
account all cells and does not distinguish between 2D surface and 3D proliferated cells. For an 
enhanced chondrogenic potential of a 3D MSC hydrogel culture, a cell number increase in the bulk 
is necessary to arrive at a more condensed and packed construct which allows a higher number of 
cell-cell contacts. This condition cannot be achieved by 2D surface proliferation only. It has been 
reported in the literature that heparin as a substrate or as coating agent is beneficial for MSC 
proliferation and differentiation due to its binding capability of proteins and direct cell receptor 
interactions.[237,238] However, these effects could not be observed in the heparin-based 3D cell 
culture as demonstrated by the presented results. Also, there are no reports of 3D hMSC 
proliferation cultures in heparin-containing hydrogels in the literature. Hence, it was hypothesized 
that heparin has probably a different influence and role on the cell behavior as 3D scaffolding 
material than as substrate for 2D culture. A possible reason for the lack of 3D cell proliferation 
under all tested conditions could be an impairment of the paracrine signaling between adjacent 
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cells by binding important cell communication molecules to heparin. This effect would not be as 
pronounced on a heparin substrate since the cells are not covered and fully surrounded by the 
sulfated GAG resulting with a significantly lower heparin-to-cell ratio in 2D culture. Furthermore, 
it has been reported that soluble heparin can have adverse effects on 2D MSC proliferation even 
at relatively low concentrations.[239] A similar effect could be responsible in the presented 3D cell 
culture model. Overall, the underlying mechanism for the impaired hMSC proliferation in 
starPEG-heparin hydrogels remained elusive and was not further investigated since it was not the 
primary objective of this work.  
To conclude, it was not possible to develop a protocol or procedure to induce hMSC proliferation 
in the 3D bulk environment of the starPEG-heparin hydrogel using well documented cell division 
stimulators to increase the cell density prior to chondrogenic induction. Higher concentrations of 
FGF-2 and low gel stiffness resulted in significant cell spreading but did not lead to an increase in 
the 3D cell count. Therefore, the chondrogenic differentiation in printed heparin-based hydrogels 
was induced and investigated directly after the 3D biofabrication step in the following experiments. 
 
4.2.2 Chondrogenesis in casted and printed hydrogels 
For the induction of the chondrogenesis of hMSC-laden hydrogels in vitro, a chondroinductive 
medium containing dexamethasone and ascorbic acid-2-phosphate and supplemented with TGF-
ß1 was used. This medium composition is widely applied for the chondrogenic differentiation of 
MSCs in scaffold-based and scaffold-free 3D cultures. The gels were printed with 5-6 million cells 
per ml and 3 different crosslinking degrees (γ = 0.5, 1.0 and 1.5) to test the influence of the gel 
stiffness on the chondrogenesis. All gels were modified with RGD which has been reported to 
have chondrosupportive properties.[240,241] Additionally, all gels were 75% MMP degradable 
indicated by a 3-to-1 molar ratio of PEG-MMP and PEG-SH as thiol-containing crosslinkers. The 
change from 100% to 75% PEG-MMP content was based on the experience with gel dissolution 
problems after a few weeks in culture in preliminary experiments. The culture period was 42 days 
which is in the range of the generally used 4 to 8 week periods for in vitro chondrogenesis 
experiments. Casted gels with 20 million cells per ml were used as controls and performance 
references. Since casted gels can be produced with higher cell concentrations, a density of 20 
million cells per ml was chosen being a reportedly favorable cell density for the chondrogenic 
differentiation of hMSCs in hydrogels.[125,242–244] In order to verify a successful differentiation, 
immunostaining for collagen type II was performed which is the most important chondrogenic 
marker while staining for collagen type I and X should indicate any signs for fibrocartilage 
formation or hypertrophy, respectively. The results are shown in Figure 16. 
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Figure 16 – Chondrogenic differentiation of hMSC in casted and printed 75% MMP-degradable starPEG-
heparin hydrogels (20 and 6 million cells per ml in casted and printed gels, respectively) for different 
crosslinking degrees (γ = 1.0 and 1.5) after 42 days in culture in chondroinductive medium. Fluorescent 
confocal images of immunostaining for collagen type II, I and X. Scale bar: 200 µm (A). Quantification of 
fluorescent signal intensity displayed with arbitrary units (a.u.) (mean ± s.d., n = 2-3 per condition) (B). 
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The fluorescent confocal microscopy images and the quantification of the immunostaining showed 
a significantly stronger staining for collagen type II and I in the casted gels compared to the printed 
versions for all tested crosslinking degrees. Collagen type X was not detected in all gels which 
proved the absence of hypertrophic development after 42 days in in vitro culture. While there was 
no difference in collagen type II deposition observable, collagen type I staining was stronger in the 
γ = 1.0 gels compared to the stiffer gels with the highest crosslinking degree (γ = 1.5). Although it 
could be expected that a stiffer cell environment would lead to a higher deposition of collagen type 
I being an integral component of the stiff bone tissue and an indicator for fibrocartilage formation, 
a similar observation with increased collagen type I synthesis in softer gels has been reported 
recently.[245] Casted and printed hydrogels with γ = 0.5 were not analyzed since they showed strong 
shrinkage and partial dissolution over the culture period. It could be observed that the hydrogels 
with low and middle crosslinking degrees (γ = 0.5 and 1.0) showed swelling tendencies in the first 
weeks of culture indicating the degradation of the hydrogel matrix by cell secreted enzymes which 
resulted in a higher water uptake. However, onset of hydrogel shrinking was observed for γ = 0.5 
gels after about 2 weeks which resulted in a significant loss of hydrogel volume due to contracting 
forces of the formed cell networks which has been shown in the previous section. For printed gels, 
this was also observed for γ = 1.0 hydrogels (Figure 17). This interplay between swelling pressure 
and cell-induced contraction of relatively soft MSC-laden hydrogels is well documented.[246] The 
experiment with a different donor showed similar results and confirmed the better performance of 
casted gels and the higher collagen type I deposition in softer gels (see appendix). 
Figure 17 – Photographs of casted and printed hMSC-laden hydrogels for chondrogenic differentiation 
after 42 days in culture. Decreasing crosslinking degrees are represented from left to right (γ = 1.5, 1.0 and 
0.5). 
The inferior performance of printed constructs could be the result of different reasons. Firstly, the 
cell concentration was about 75% lower than in the casted versions which would lead to a lower 
number of possible cell-cell contacts and a lower local concentration of important paracrine 
signaling molecules. This was considered as the major factor for the impaired chondrogenic 
differentiation and cartilaginous matrix production in printed hydrogel constructs. Secondly, the 
fast gelation time for printed hydrogels could result in a less effective crosslinking due to 
insufficient gel precursor mixing which would lead to a lower gel stiffness and a heterogeneous 
Casted gels Printed gels 
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hydrogel environment with PEG and heparin-enriched domains. Finally, the shear stress from the 
droplet ejection could have negatively impacted the cells and their differentiation potential even 
though it was demonstrated in the former section that a high cell viability and functionality was 
maintained after the printing process.  
The presented results suggested that inkjet bioprinting of hMSC-laden hydrogels for 
chondrogenesis was not a reasonable option to pursue. Besides the demonstrated inferior matrix 
synthesis, the production efforts in order to fabricate printed constructs were significantly higher 
than the simple casting of cell-laden hydrogels. To print a hydrogel with a comparable size (25 µl), 
a time frame of about 45 minutes per construct was required without considering occurrent 
clocking issues and “aging” of the cell-containing gel precursor solutions due to cell aggregation. 
Furthermore, capped cell and polymer concentrations for printing added to the list of limitations. 
Therefore, it was decided to not continue the printing of layered hydrogel constructs for 
chondrogenic differentiation experiments since there was no noteworthy advantage, but instead 
more disadvantages of 3D inkjet bioprinting of starPEG-heparin hydrogels observable. Hence, the 
further focus in future experiments was switched towards a better understanding of the 
chondrogenesis in casted starPEG-heparin hydrogels and the exploitation of favorable intrinsic 
biomaterial properties to enhance the chondrogenic differentiation and cartilaginous matrix 
production. 
 
4.2.3 Chondrogenic Differentiation in starPEG-heparin hydrogels 
The results of the former section showed the best results concerning matrix production and matrix 
composition (here represented by the ratio of the staining intensity of collagen type II to type I) 
for the casted 75% MMP-degradable, RGD-modified starPEG-heparin hydrogels with a 
crosslinking degree of γ = 1.5. Therefore, this hydrogel composition was considered as the standard 
condition and the reference hydrogel being used in the following experiments.  
To further demonstrate the feasibility of the chondrogenesis of differentiated hMSCs in heparin-
based hydrogels, casted hydrogels with 3 different donors were cultured and evaluated with 
immunohistochemistry. For performance references, scaffold-free hMSC micromass cultures were 
used. Generally, high density cell pellet cultures formed by centrifugation of cell suspensions into 
conical Falcon tubes to provide 3D cellular constructs are the standard method to perform 
chondrogenic differentiation experiments with MSCs. However, it has been reported that due to 
necrosis and the lack of differentiation in the center region as well as the deposition of collagen 
type I and X pellet cultures are not ideal to reproduce hyaline cartilage in vitro. Micromass culture 
systems produced by cellular self-assembly from highly concentrated cell suspensions have been 
shown to deliver superior results with a reduced expression of collagen type I and X.[247] The results 
of the chondrogenic differentiation experiment with 3 different donors are shown in Figure 18. 
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Figure 18 – Chondrogenic differentiation in casted, 75% MMP-degradable, RGD-modified hMSC-laden 
hydrogels γ = 1.5 (= standard composition) and in hMSC micromass cultures after 42 days in culture in 
chondroinductive medium. Fluorescent confocal images of the immunostaining for collagen type II, I and 
X. Scale bar: 200 µm (A). Quantification of fluorescent signal intensity (mean ± s.d., n = 3 per condition 
and donor) (B). 
For all 3 donors, successful chondrogenic differentiation of hMSCs in starPEG-heparin hydrogels 
indicated by a positive and evenly distributed collagen type II staining was observable. The staining 
intensity was comparable with the micromass culture references. Collagen type I was stained only 
to a relatively minor extent in the hydrogel and the micromass controls whereas type X was not 
detected for all conditions and donors. There was also no significant difference observable between 
the different donors concerning the staining intensity for the different markers. In general, Safranin 
O or toluidine blue staining is additionally performed to visualize and analyze the production of 
sulfated GAGs being one of the most important indicators for a successful chondrogenic 
differentiation. However, due to the high abundance of heparin in the hydrogel which would result 
in a very strong background signal, GAG staining and quantification assays for sulfated GAGs 
were not performed. The presented results demonstrate the successful, donor-independent 
chondrogenesis with similar outcomes compared to the scaffold-free controls concerning the 
positive staining for cartilage-specific markers and the lack or low staining for hypertrophic and 
fibrocartilage-specific markers, respectively.  
Next, the temporal development of the chondrogenic differentiation indicated by the progressing 
matrix deposition was investigated. The interest was particularly on the onset of the collagen type 
II matrix production and potentially intermediate depositions of collagen type I and X during the 
culture period. To further characterize the biochemical composition and mechanical properties of 
the engineered constructs, a total collagen assay and AFM nanoindentation measurements were 
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Figure 19 – Temporal development of the chondrogenic differentiation and cartilaginous matrix production 
in starPEG-heparin hydrogels with standard composition in weekly intervals over 42 days in culture. 
Fluorescent confocal microscopy images of immunohistochemical staining for collagen type II, I and X. 
Scale bar: 200 µm (A). Quantitative analysis of fluorescent intensity (B), evaluation of mechanical properties 
by measuring the elastic modulus with AFM nanoindentation (C) and quantification of total collagen content 
being normalized to the tissue wet weight (D) (mean ± s.d., n = 3 per condition). 
The immunohistochemical staining showed the onset of the chondrogenesis after 14 days indicated 
by the first positive staining for collagen type II. Henceforward, the staining intensity increased 
steadily over the next weeks until a uniformly distributed matrix deposition was reached after 42 
days. The biggest incremental gain in staining intensity was observable in the last week of the 
culture. Positive collagen type I staining firstly appeared after 42 days in culture while, in accordance 
with the previous results, there was no collagen type X detectable over the whole culture period. It 
is noteworthy to mention that the progressing collagen type II matrix deposition was evenly located 
over the whole hydrogel construct which points towards a sufficient supply of nutrients and growth 
factors to the cells in the hydrogel center. If the diffusion of TGF-ß1 and other nutrients through 
the hydrogel was impaired due to a possibly too strong sequestration by heparin, the matrix 
deposition would have been observable probably only at the gel periphery with undifferentiated 
cells in the center over the culture period. Additionally, the data from the immunostainings were 
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of hydroxyproline being a collagen-specific amino acid. The assay detected the first collagenous 
matrix production already after 7 days in culture. The final value of 0.4 – 0.5% (w/w) after 42 days 
was in the range of published values for tissue engineered cartilage constructs made of 
chondrogenic differentiated MSCs in hydrogels, but is still about 1.5 orders of magnitude lower 
than the collagen content in native articular cartilage.[242,243,248] Interestingly, the hydrogel stiffness 
did not increase despite the supportive matrix deposition. In fact, the mean elastic modulus was 
slightly lower after 42 days in culture. This counterintuitive result could be possibly explained by a 
stronger hydrogel degradation which was not offset by the deposited collagenous matrix. An 
observed swelling and increase in total hydrogel volume during the culture period supported this 
hypothesis. The results with a different donor led to similar outcomes (see appendix). The total 
collagen content generally reached a value of around 0.5% (w/w) of the wet weight while there was 
no increase in hydrogel stiffness observable. Therefore, the results suggested that these donor-
independent effects only relied on the cell type, the hydrogel composition and the culture 
conditions.  
Despite the successful chondrogenic differentiation indicated by the homogeneously distributed 
collagen type II deposition with a relatively low collagen type I production and the absence of 
hypertrophic markers, the lack of an increasing hydrogel stiffness as well as the relatively low 
collagen content were seen as major issues that needed to be addressed since the biomechanical 
properties of engineered cartilage constructs play a pivotal role and are required to be in the range 
of the native tissue in order to be considered for potential cartilage repair approaches.[249] It was 
hypothesized that the stimulation of the matrix production would lead to a denser collagen network 
and a more pronounced cartilage-like ECM deposition which would in turn ameliorate the 
biomechanical properties of the cell-laden hydrogel constructs. However, the stimuli were required 
to be applied under controlled conditions to avoid terminal differentiation and fibrocartilage 
formation. Therefore, several strategies were derived and applied to tackle these problems which 
are presented in the following section. 
 
Growth factor combinations and macromolecular crowding to stimulate ECM production 
The chondrogenesis of MSCs is reported to be induced by a wide range of growth factors and 
smaller molecules. TGF-ß1 and -ß3 are the most commonly used cues for stem cell-based cartilage 
tissue engineering approaches under scaffold-free and -based conditions. However, only one 
growth factor is generally applied at once. In contrast, the embryonic development of cartilage is 
regulated and controlled by a large number of growth factors and soluble factors which have 
different roles and effects at various points along the timeline of the chondrogenesis. For in vitro 
and in vivo cartilage tissue engineering applications, there is still little known about the influence and 
mechanisms of applied growth factor cocktails with different compositions and concentrations on 
the chondrogenic differentiation of stem cells. A few reports have presented the use of dual or 
4   Results and Discussion 
 
71 
triple growth factor strategies.[111,250–252] One of the most interesting studies in this regard was 
reported by Karimi et al. who designed a developmentally inspired approach using TGF-ß1 in 
combination with either IGF-1 or BMP-7 in hMSC-laden PEG-based hydrogels to replicate the 
zonal structure of articular cartilage.[111] IGF-1 as highly anabolic growth factor was applied to 
increase the cartilaginous matrix production in the middle zone while BMP-7 was intended to 
engineer superficial chondrocytes with the capability of lubricin production. The results showed a 
strong increase in collagen and GAG content which was mainly driven by the IGF-1 
supplementation while BMP-7 significantly increased the lubricin expression. Therefore, it was 
decided to use a similar approach to stimulate the chondrogenesis in starPEG-heparin hydrogels 
with an IGF-1 preloading combined with a dual BMP-7/TGF-ß1 external supply from the 
medium. Additionally, it was considered that BMP-7 as a heparin binding molecule would be bound 
and stabilized by the hydrogel matrix which would potentially further increase its bioactivity. The 
results of this experiment are shown in Figure 20. 
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Figure 20 – Influence of a combined growth factor approach with preloaded IGF-1 and BMP-7 medium 
supplementation on the hMSC chondrogenesis in starPEG-heparin hydrogels with standard composition. 
Control gels were incubated in standard chondroinductive medium containing only TGF-1. Fluorescent 
confocal microscopy images of the immunostaining for collagen type II, I and X after 42 days in culture. 
Scale bar: 200 µm (A). Quantification of fluorescent signal intensity (B) and total collagen content 
normalized to the tissue wet weight (C) (mean ± s.d., n = 2-3 per condition). 
The immunohistochemical staining and the quantification of the fluorescent signal intensity 
showed no significant differences in the staining intensity and distribution of the different collagens 
for all tested conditions compared to the control samples which were incubated in the standard 
chondroinductive medium supplemented only with TGF-ß1. Neither the single IGF-1 preloading, 
the BMP-7 supplementation nor the combined application for a triple growth factor application 
strategy resulted in an increased matrix deposition indicated by similar values for the total collagen 
content despite the reported benefits of these growth factors on the cartilage-like matrix 
production.[253,254] Lubricin was also not detected by immunostaining. It must be mentioned that 
only one concentration per growth factor was used which bears the risk of having missed the 
“window of opportunity” in the case optimized growth factor concentrations would have been 
applied. Furthermore, temporary and timely dependent growth factor administrations could be 
additional options to be investigated in order to present the required signaling molecules during 
intended stages of the differentiation while avoiding potentially adverse effects in other stages. To 
address these issues, high throughput combinatorial approaches could be the method of choice to 
extent the understanding of growth factor combinations for in vitro cartilage tissue engineering 
applications. However, the presented results led to the decision to not continue this approach since 
there was no evidence for any detectable advantages when several growth factors were used in a 
combined manner for hMSC chondrogenesis in starPEG-heparin hydrogels. 
Besides the administration with multiple biochemical cues, the application of macromolecular 
crowding (MMC) was considered as another promising strategy to stimulate the chondrogenesis 
and matrix deposition in hMSC-laden starPEG-heparin hydrogels. The rational was that MMC 
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important matrix-producing enzymes, growth factors and other signaling molecules which are 
responsible for a successful chondrogenic differentiation in the hydrogel. This would possibly lead 
to a more biomimetic environment being found during the developmental mesenchymal 
condensation process or in the highly dense ECM of native cartilage tissue. MMC uses preferably 
bioinert macromolecules as medium additives that occupy a considerable volume fraction which 
eventually results in higher effective concentrations of other solutes such as ECM precursors. It 
has been shown that MMC enhances the ECM deposition of cultured MSCs up to 80 fold by 
altering the local cellular environment to arrive at in vivo-like molecular density profiles where higher 
enzymatic conversion rates lead to a more pronounced matrix production and organization.[255,256] 
In contrast, Chen et al. reported an impaired cartilaginous ECM deposition in 3D chondrocyte 
cultures with both scaffold-free and -based methods compared with the 2D culture.[257] Despite 
these insights, it was decided to apply MMC with different crowder concentrations (indicated as 
fractional volume occupancy (FVO)) due to potential benefits of a crowded extracellular 
environment for the chondrogenic differentiation of MSCs by possibly mimicking the condensed 
conditions of the developmental process of native MSC-based chondrogenesis. 
Polyvinylpyrrolidone (40 kDa) was chosen as crowder substance since it has been demonstrated to 
enhance the ECM production and proliferation of cultured MSCs.[258] The results of the experiment 
are shown in Figure 21. 
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Figure 21 – Influence of MMC with different crowder concentrations on the chondrogenic differentiation 
of hMSCs in starPEG-heparin hydrogels with standard composition after 42 days in culture in normal 
chondroinductive medium. The crowder content is indicated by the fractional volume occupancy (FVO) as 
% of the total volume of the medium. Fluorescent confocal images of the immunostaining for collagen type 
II, I and X after 42 days in culture. Scale bar: 200 µm (A). Quantification of fluorescent signal intensity (B) 
and total collagen content normalized to the tissue wet weight (C) (mean ± s.d., n = 3 per condition). 
The immunohistochemical staining and the total collagen assay showed a decreasing overall matrix 
deposition when the crowder concentration was increased. The ECM production was almost 
indirectly proportional to the applied crowder content. At the highest concentration (36%), there 
was no positive staining for all tested collagens, while the value of the total collagen content was in 
the range of day 0 samples as demonstrated in former experiments (see Figure 19C). This clearly 
indicated that MMC had a directly negative impact on the chondrogenesis which eventually led to 
a complete inhibition of the ECM deposition at the highest crowder concentration. These findings 
were therefore in line with the earlier mentioned report of a reduced matrix production when MMC 
was applied in 3D chondrocyte culture applications and could now be confirmed for MSC-based 
3D hydrogel cultures. However, the underlying mechanism for this impaired performance 
compared to the stimulatory effects observed in 2D cultures remained elusive. Possible 
explanations could be the unintended activation of matrix degrading enzymes or the inhibition of 
the metabolism by hindered metabolic waste disposal in an increasing artificially crowded cellular 
environment.[257] Based on the presented results, it was decided to not further investigate and 
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4.2.4 Summary and conclusion 
In the second part of the thesis, it was demonstrated that the chondrogenic differentiation of 
hMSCs in MMP-degradable, RGD-modified starPEG-heparin hydrogels could be successfully 
executed which was indicated by a homogeneously distributed deposition of cartilage-specific 
collagen type II with low levels of collagen type I and the absence of collagen type X being markers 
for fibrocartilage and hypertrophy, respectively. The inkjet bioprinting of hMSC-laden hydrogels 
did not prove to be a pursuable option due to an inferior chondrogenic performance displayed by 
a significantly lower staining intensity for collagen type II compared to the casted hydrogels which 
in turn showed similar staining intensities and matrix compositions as hMSC micromass cultures 
being used as scaffold-free positive controls. Furthermore, it was not possible to trigger the hMSC 
proliferation in the 3D bulk hydrogel by using potent biochemical stimulators at varying hydrogel 
stiffness levels which resulted only in 3D cell spreading and 2D surface cell proliferation in case of 
soft hydrogels. In order to ameliorate the mechanical properties and the cartilaginous ECM density 
in the engineered hydrogel constructs which were still significantly lower than the values of native 
articular cartilage, external stimulatory approaches including an IGF-1/BMP-7/TGF-ß1 triple 
growth factor administration strategy as well as macromolecular crowding from the medium were 
applied. However, these attempts did not show to have any beneficial effects on the matrix 
synthesis whereas MMC even proved to be inhibitory on the hMSC-based chondrogenesis.  
Eventually, this led to the conclusion that a selected alteration of intrinsic hydrogel parameters 
should be investigated in the following experiments to get a deeper insight on the chondrogenic 
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4.3 Modulation of hydrogel properties and their 
influence on the chondrogenesis of hMSCs 
Since it has been shown in the former section that the chondrogenesis of hMSCs in starPEG-
heparin hydrogels with the standard gel composition resulted in engineered cartilage constructs 
with particularly insufficient mechanical properties despite the supplementary application of several 
biochemical stimuli, it was hypothesized that the modulation of certain hydrogel properties would 
be beneficial for an enhanced cartilaginous ECM deposition to fabricate improved biomimetic 
scaffolds and to better understand the driving forces and potential limiting factors of the hydrogel. 
The modular design of the starPEG-heparin system provided the possibility to alter a variety of 
parameters such as the degradability, stiffness and the content of bioactive cues including the 
heparin and RGD concentration. It has been mentioned in the former section that full MMP 
degradability indicated by using only PEG-MMP as crosslinker had strong hydrogel shrinking and 
dissolution problems as consequence which resulted in the reduction to the 75% MMP 
degradability level as standard condition. However, since the hydrogel stiffness did not increase 
using this composition despite the deposition of cartilaginous ECM over the culture period of 6 
weeks, it was hypothesized that the enzymatic degradation of the hydrogel components was still 
too high and a reduction of the MMP degradability by changing the ratio of PEG-MMP to PEG-
SH would be beneficial. Concerning the hydrogel stiffness, it has been shown that the stiffest 
hydrogels with a crosslinking degree of γ = 1.5 at a polymer solid content of about 5% delivered 
the best results with the lowest collagen type I deposition. The use of a higher overall solid content 
while maintaining the ratios of the gel precursor polymers was considered as an additional option 
to further increase the hydrogel stiffness. However, it would have also resulted in a higher heparin 
density and a different cell-to-heparin ratio in the hydrogel. This was not seen as a pursuable option 
since it was also hypothesized that besides the hydrogel degradability, the relatively high heparin 
concentration could be another potential factor that would have an impact on the ECM production 
of the embedded hMSCs. Based on these considerations, both the MMP degradability and the 
heparin content were systematically varied to investigate their influence on the chondrogenesis. 
 
4.3.1 Influence of the MMP-degradability  
In order to modify the enzymatic degradability level of the hydrogel, the PEG-MMP content was 
altered in 20% steps from 60% to 0% resulting in a non-degradable starPEG-heparin hydrogel in 
the latter case. The standard 75% MMP-degradable hydrogel was used as control. The medium and 
the culture period were kept at the standard conditions. The results of this experiment for one 
donor are shown in Figure 22. 
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Figure 22 – Influence of different MMP degradability levels on the chondrogenic differentiation of hMSC-
laden starPEG-heparin hydrogels for donor 1. Fluorescent confocal images of the immunostaining for 
collagen type II, I and X after 42 days in culture. Scale bar: 200 µm (A). Evaluation of mechanical properties 
by measuring the elastic modulus with AFM nanoindentation (B) and total collagen content normalized to 
the tissue wet weight (C) (mean ± s.d., n = 2-3 per condition). 
The immunohistochemical staining and the hydroxyproline assay of donor 1 showed a significantly 
impaired matrix production for all lower MMP degradability levels compared to the control 
condition indicated by a lower staining intensity for collagen type II and type I and a lower total 
collagen content. As it was observed in previous experiments, collagen type X was not detected. 
Interestingly, there was no significant difference observable between the 0% and 60% levels which 
indicated that the chondrogenic differentiation was also possible in non-MMP degradable 
hydrogels but at a much lower magnitude while only at a higher degradability the matrix production 
was significantly increased. However, the results of donor 2 displayed similar levels of the total 
collagen deposition and matrix composition for all tested MMP degradability conditions (see 
appendix). These findings indicate that the influence of the MMP degradability was rather donor-
dependent which nevertheless did not result in an identifiable trend towards an improved 
chondrogenesis. Furthermore, the lack of an increased gel stiffness for all tested conditions and 
donors measured by AFM nanoindentation confirmed the relatively negligible impact of the MMP 
degradability on the overall outcome for the fabrication of biomechanically enhanced hydrogel 
constructs for cartilage tissue engineering. This also falsified the initial hypothesis that a higher 
hydrogel degradability would offset the mechanosupportive effects of the deposited ECM since 
even non-MMP degradable gels with a similar collagen content compared to the 75% version did 
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4.3.2 Influence of the heparin content 
The second important hydrogel parameter that was believed to have a significant influence on the 
chondrogenesis of hMSCs and the extent of the cartilaginous ECM deposition was the heparin 
concentration in the hydrogel. It was hypothesized that the growth factor binding and stabilizing 
properties of heparin which were regarded as beneficial for the TGF-1 administration could also 
have a negative impact on the cell-cell communication and interaction which would eventually 
impair the chondrogenic differentiation and diminish the overall matrix production. On the other 
hand, there are several reports in the literature that present an efficient chondrogenesis of 
chondrocytes embedded in heparin-based hydrogels resulting in the formation of cartilage-like 
tissues where the mentioned features of heparin were viewed as important key properties.[259–261] 
However, the chondrogenic differentiation of hMSCs in hydrogels with heparin as building block 
has not yet been described while it was successfully used as an additive cue in the form of growth 
factor delivery vehicles in several MSC-based cartilage tissue engineering approaches.[262–264]  
To prove the outlined hypothesis, it was decided to systematically investigate the influence of a 
progressively reducing heparin content on the chondrogenic performance. The heparin 
concentration was gradually lowered to 50%, 10% and 1% of its original value (1.5 mM) by 
substituting the heparin-maleimide component with starPEG-maleimide in order to maintain a 
stable hydrogel stiffness and a constant polymer solid content of about 5% with the intent to 
decouple the change in the density of bioactive cues from the mechanical properties for the 
different conditions. With this experimental design it was possible to account any potential changes 
solely to the altered heparin concentration. The 0% and 100% heparin gels representing the pure 
PEG gel and the standard starPEG-heparin hydrogel were used as controls, respectively. The 75% 
MMP-degradability level, the degree of RGD functionalization as well as the medium composition 
remained unchanged for all tested conditions. The results of this experiment for donor 1 are shown 
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Figure 23 – Influence of different heparin contents on the chondrogenic differentiation of hMSC-laden 
starPEG-heparin and pure starPEG hydrogels for donor 1. Fluorescent confocal microscopy images of 
immunostaining for collagen type II, I and X after 42 days in culture. Scale bar: 200 µm (A). Quantification 
of fluorescent signal intensity (B) and analysis of collagenous matrix composition indicated by the signal 
intensity ratio of collagen type II to I (C). Measurement of the elastic modulus on day 0 and the end of the 
culture (day 42) by AFM nanoindentation (D) and total collagen content normalized to the tissue wet weight 
(E) (mean ± s.d., n = 3 per condition). 
The analysis of the immunohistochemical staining and the quantification of the fluorescent signal 
intensity did not show any significant differences for the stained collagens under all tested 
conditions for donor 1. Additionally, the matrix composition here defined as the ratio of the 
staining intensity for collagen type II to type I was also not affected by the altered heparin 
concentration. With regards to the morphology of the produced matrix, it could be observed that 
at low heparin densities (< 10%; < 0.15 mM) as well as in the pure PEG gels the collagen was 
deposited in a more compartmentalized fashion around the cells with unstained, collagen-free areas 
in between whereas with an increasing heparin content the matrix distribution became more 
homogeneous culminating in the evenly spreaded “cloud-like” appearance for the standard “100%” 
starPEG-heparin hydrogels as it was displayed in former experiments. This trend was also 
observable for other donors and can therefore be accounted as immediate effect of the heparin on 
the ECM deposition fashion (see appendix for the immunostaining and quantitative analysis data 
for donor 2 and 3). In contrast to the staining outcomes, the quantification of the total collagen 
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concentration resulting in the highest level for the heparin-free, pure PEG gels which was 
significantly higher than in the standard starPEG-heparin hydrogels. This had a direct influence on 
the mechanical properties of the gel constructs as indicated by a significant increase of the elastic 
modulus along with the higher collagen content for low and heparin-free hydrogels. In addition, a 
toluidine blue staining to visualize sulfated GAGs showed a significant increase in deposited GAG-
rich proteoglycans in pure PEG gels and low heparin-containing hydrogels (< 10%) after 42 days 
in culture when compared to day 0 samples indicated by a strong dark purple color of the stained 
day 42 tissue samples (Figure 25). Besides the deposition of a collagen type II-rich matrix, the 
synthesis of sulfated GAG-containing proteoglycans is generally regarded as another indicator for 
a successful chondrogenic differentiation. However, for the standard starPEG-heparin hydrogel 
composition which already showed a strong background staining at day 0 due to the high heparin 
concentration, there was not such a significant difference in the staining intensity observable after 
42 days in culture. 
Besides the outcomes of the histological stainings, the biochemical composition and the 
mechanical properties, the cell morphology was also different at variable heparin concentrations 
(Figure 24). In the 100% heparin gel, the differentiated cells displayed a spherical, chondrocyte-
like shape while with a decreasing heparin content, a growing cell elongation was observable. At 
the low and heparin-free conditions, cells had a fibroblastic and spreaded morphology and formed 
dense cellular networks comparable to previously observed hMSC networks in γ = 0.5 starPEG-
heparin gels under expansion conditions (see Figure 15).  
Figure 24 – Bright field images of differentiated hMSCs in starPEG-heparin hydrogels with different 
heparin contents (indicated as % of the original concentration) after 42 days in culture. Scale bar: 100 µm. 
0% 1% 10% 
50% 100% 
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Figure 25 – Bright field microscopy images of the toluidine blue staining for sulfated GAG visualization of 
hMSC-laden starPEG-heparin hydrogels with different heparin contents (indicated as % of the original 
concentration) at day 0 and after 42 days in culture. Scale bar: 100 µm (inset scale bar: 500 µm). 





4   Results and Discussion 
 
84 
Interestingly, this cell spreading behavior was expected to be observable only in very soft hydrogel 
environments but the similar stiffness levels in the range of 3-4 kPa for the varying heparin contents 
on day 0 proved that this effect was based on the different initial and developing 
microenvironments that were formed by the cells over the culture period in response to the 
different heparin concentrations. In general, hMSC spreading is related to an impaired 
chondrogenesis and the risk of an upregulated expression of fibrocartilage markers.[265,266] However, 
the presented results do not support these statements since the matrix production was increased in 
low heparin hydrogels which contained spreaded cells and the extend of collagen type I deposition 
was comparable for all heparin concentrations. 
The observations of different biochemical and mechanical properties for varying heparin 
concentrations were made for all tested donors which displayed similar outcomes. Therefore, it 
was concluded that heparin had a donor-independent impairing effect on the chondrogenesis and 
the overall cartilaginous matrix production of hMSCs at higher concentrations in starPEG-heparin 
hydrogels (Figure 26). When compared with the impact of the other tested material properties, 
the heparin content was therefore considered as the key influential factor whose alteration directly 
resulted in significant changes in the mechanical and biochemical properties of the cell-laden 
engineered constructs.  
Figure 26 – Overview of elastic moduli measured by AFM nanoindentation (A) and total collagen contents 
(B) for all tested donors (mean ± s.d., n = 3 per condition and donor). 
Although the underlying mechanism remained elusive, it was hypothesized that the interplay of 2 
opposing factors could explain the inferior performance of the heparin-based hydrogels. As already 
mentioned, the relatively high concentration of the strongly protein-binding heparin could impair 
the activity of cellular receptors as well as the cell-cell communication of embedded hMSCs 
mediated by soluble signaling molecules which would negatively impact the chondrogenesis and 
the extent of the matrix deposition compared to the pure PEG gels. Simultaneously, potential 
hydrolysis of the disaccharide subunits of heparin in addition to the enzymatic cleavage of the 
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MMP-degradable peptide linkers would result in a faster degradable hydrogel than the only MMP-
degradable pure PEG gels which would completely offset the stiffening effect of the already 
reduced matrix production. This combined effect would in turn lead to the observed stagnation of 
the hydrogel stiffness. An upregulation of secreted MMPs in heparin-containing hydrogels as an 
alternative explanation could be theoretically excluded since non-MMP degradable starPEG-
heparin hydrogels did not show an improved stiffness while having a similar total collagen content 
when compared to the degradable versions (see appendix for chapter 4.3 “Influence of the MMP 
degradability”). 
Based on the presented results, further investigations of the influence of heparin were required. 
The most protruding property of this sulfated GAG is its growth factor binding and stabilizing 
capability. Since the TGF-ß1 being essential for the chondrogenic induction was so far supplied 
mostly externally via medium changes in all performed experiments, it was necessary to examine 
the influence of different TGF-ß1 preloading concentrations in hydrogels with graded heparin 
contents on the chondrogenic differentiation of embedded hMSCs. This would be particularly 
important for potential in vivo applications where growth factor stability and delivery can play a 
pivotal role for a successful tissue formation.[267] 
 
4.3.3 Influence of different TGF-ß1 preloadings in starPEG-
heparin hydrogels with graded heparin contents 
Despite the described impairing effect of heparin in the 3D in vitro culture, this outcome cannot 
offhandedly be projected into the in vivo situation. An important difference of in vitro and in vivo 
cultures is the lack of a controlled supplementation of defined growth factor-containing media with 
regular changes and a high medium-to-sample ratio in the latter case. Therefore, it can be 
hypothesized that the in vitro performance of the pure PEG gels was also based on the constant 
supply with fresh TGF-ß1 from regular medium changes whereas in case being used for an implant 
into an (osteo)-chondral defect the avascular nature of the native cartilage could pose a potential 
risk for an insufficient supply of soluble cues from the surrounding tissue. In this case, a sustainable 
in-situ growth factor delivery and release of TGF-ß1 from the starPEG-heparin hydrogel could 
circumvent this issue and would provide the embedded as well as the residing cells with stimulatory 
doses over extended periods of time. Furthermore, heparin could thermodynamically stabilize 
TGF-ß1 which has a reportedly short half-life time in vivo.[268,269] Based on these assumptions, an in 
vitro assay with different TGF-ß1 preloading concentrations in hMSC-laden starPEG-heparin 
hydrogels with graded heparin contents was performed to test the stated hypothesis of a supporting 
growth factor stabilizing and presenting effect of heparin-containing hydrogels compared to PEG-
only gels. As testable heparin concentrations, 1% and 5% of the standard starPEG-heparin 
hydrogels (representing 15 and 75 µM, respectively) were chosen since it has been shown in the 
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former experiments that significant improvements in the matrix deposition and gel stiffness only 
occurred for conditions with < 10% heparin content. TGF-ß1 was loaded only into the hydrogel 
by mixing with the gel precursor solutions prior to the gelation. The hydrogels were then cultured 
in TGF-ß1-free chondroinductive medium for 42 days. The results of this experiment are shown 
in Figure 27. 
 
 
Figure 27 is continued on the next page 
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Figure 27 is continued on the next page 
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Figure 27 – Preloading of different TGF-ß1 concentrations in graded heparin-containing and pure PEG 
gels. Fluorescent confocal microscopy images of immunostaining for collagen type II and I after 42 days in 
culture. Scale bar: 200 µm (A). Measurement of the elastic modulus at day 42 by AFM nanoindentation (B) 
and total collagen content normalized to the tissue wet weight (C) (mean ± s.d., n = 3 per condition). 
The fluorescent images of the immunochemical staining showed significant differences in 
deposited collagen type II among the graded heparin-containing gels and when compared to the 
pure PEG gel controls. In the heparin-containing gels, the 1% condition showed no matrix 
deposition for the 500 and 1000 ng/ml TGF-ß1 preloading while for 2000 ng/ml collagen type II 
was deposited at the gel periphery which was strongly increased in case of the 4000 ng/ml 
concentration. Similar observations were made for the 5% condition but had a lower staining 
intensity and a decreased number of collagen type II-positive cells compared to the 1% condition, 
particularly at the 2000 ng/ml concentration. For the standard starPEG-heparin hydrogels, no 
positive staining for collagen type II was observed for all tested TGF-ß1 preloading concentrations. 
Furthermore, no collagen type I and X was observed in all tested heparin-containing gel conditions. 
In contrast, pure PEG gels showed the appearance of peripheral collagen type II already at the 
lowest 500 ng/ml preloading concentration with a progressively increasing abundance at higher 
growth factor preloadings. At 4000 ng/ml, positive collagen type II staining was observable over 
the whole hydrogel and collagen type I deposition was detectable in the gel center. The mechanical 
properties and the total collagen content were generally in accordance with the staining outcomes. 
The elastic modulus and the collagen content increased with higher TGF-ß1 preloadings in pure 
PEG gels. From the 1000 to 4000 ng/ml concentrations, the gel stiffnesses were significantly higher 
than for all heparin-containing hydrogels which did not show any increase regardless of the TGF-
ß1 content. At the lowest TGF-ß1 concentration, there was no difference in the mechanical 
properties observable for the different gel compositions. However, this trend was not linked to the 
total collagen content in heparin-based hydrogels which showed higher matrix depositions for the 
2000 and 4000 ng/ml condition in the 1% and 5% heparin gels. Only the 100% heparin gels did 
not display any significant changes in mechanical and biochemical properties for all tested growth 
factor concentrations. Interestingly, despite the upregulated collagen production at high TGF-ß1 
preloading levels (2000 and 4000 ng/ml), the gel stiffness did not increase in the low-heparin 
hydrogels as it would be expected based on the previously presented results (see Figure 26). In 
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particular, the difference between the heparin-containing and the PEG hydrogels for the 4000 
ng/ml condition was remarkable in this context. Therefore, it could be argued that the mechanical 
properties of the engineered constructs did not solely depend on the density of the produced 
collagenous matrix but also on the fibril formation and organization of the collagen fibers during 
the matrix neogenesis which could have been influenced by the presence of heparin. It has been 
reported that heparin can modulate the collagen fibril formation even at relatively low 
concentrations which eventually leads to changes in the collagen network with an increased number 
of free-standing fiber ends compared to heparin-free controls.[270,271] This could result in a reduced 
mechanical integrity which would explain the observed non-correlation of the biochemical 
compositions and the hydrogel stiffnesses. However, further investigations would be necessary to 
prove or falsify this hypothesis.  
When these TGF-ß1 preloading-only data were compared with the outcomes of the external 
growth factor supplementation strategy in graded heparin-containing hydrogels (see Figure 23 and 
26), it could be observed that similar collagen contents were achieved for the varying heparin 
contents at high TGF-ß1 concentrations. Surprisingly, this was particularly the case for the pure 
PEG gels which also had comparable gel stiffness levels. These findings therefore falsified the 
previously mentioned hypothesis that successful chondrogenic differentiation in low-heparin and 
pure PEG gels was only possible due to a sustained external TGF-ß1 supply via regular medium 
changes. The increasing matrix production in PEG gels which was already detected at the lowest, 
500 ng/ml TGF-ß1 concentration and that positively correlated with higher growth factor 
preloadings was a potential indicator of a prolonged activity and retention of TGF-ß1 in these 
hydrogels which were originally believed to deliver an inferior chondrogenic performance due to 
an initial absence of growth factor-binding and -stabilizing sulfated GAG units in the gel network. 
A possible explanation of these observations could be that the hMSCs in heparin-free hydrogels 
underwent a faster chondrogenic differentiation compared to heparin-based hydrogels which 
would yield an early deposition of sulfated GAG rich, cartilaginous ECM that could bind the 
embedded TGF-ß1 before degradation issues and fast release kinetics would lead to an insufficient 
level of this biochemical factor in the hydrogel constructs which is needed to induce and maintain 
the in vitro chondrogenesis. In this regard, the strong GAG staining observed in pure PEG gels 
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4.3.4 Summary and conclusion 
In the third part of the thesis, it could be demonstrated that the alteration of selected hydrogel 
material parameters could directly influence the chondrogenic differentiation and the extend of the 
cartilage-like matrix production of embedded hMSCs in starPEG-heparin hydrogels. The variation 
of the enzymatic MMP-mediated hydrogel degradability which was altered from highly degradable 
to non-degradable generated donor-dependent responses regarding the density of the deposited 
collagenous matrix where one donor showed a significantly impaired ECM production at lower 
degradability levels while another donor was not influenced as being demonstrated by comparable 
staining outcomes and similar total collagen contents at all applied PEG-MMP contents. 
Interestingly, the hydrogel stiffnesses did not increase regardless of the amount of deposited matrix 
for all tested conditions and donors. The reduction of the heparin content while maintaining a 
constant initial gel stiffness proved to be a key trigger to enhance the biochemical and mechanical 
properties of the engineered hydrogel constructs. For all tested donors, the total collagen content 
and the hydrogel stiffness increased with reducing heparin concentrations which eventually resulted 
in significant differences of the mentioned properties in low heparin and pure PEG gels compared 
to the standard starPEG-heparin hydrogels after 42 days in culture. However, the collagen matrix 
composition did not tend to be influenced as it was indicated by immunohistochemical staining 
which showed comparable intensities for collagen type II and type I for all tested heparin contents. 
This impairing effect of heparin was also observed when different TGF-ß1 preloading 
concentrations were tested in graded heparin hydrogels under growth factor-free medium 
conditions where pure PEG gels outperformed heparin-containing hydrogels. Therefore, these 
results clearly pointed out the relevance of heparin as bioactive hydrogel component with the ability 
to modulate the chondrogenic differentiation of hMSCs and the necessity to investigate the 















Damage of the articular cartilage which leads to the development of osteoarthritis (OA) is a 
growing problem of ageing societies in regard to the high incidence with older and overweight 
people. The consequences are an impaired mobility accompanied with severe pain and the risk of 
permanent disability for the affected persons. Due the quiescent state of the residing chondrocytes 
and the avascular and aneural nature of cartilaginous tissues, intrinsic repair is generally limited, 
and initial damage at the articular surface is often unrecognized which makes an early diagnosis 
difficult to be achieved since most patients initiate the look for medical advice upon an arising 
indication of disease-related symptoms like increasing pain when OA is already in a progressed 
stage for the majority of cases. In addition, the lack of reliable markers for the detection of the 
important initial phase forces clinicians to treat mainly late-stage OA.  
Therefore, medical and clinical research primarily focuses on the development of regenerative 
approaches to stop the progress of the joint degeneration and to achieve a long-term cartilage 
repair. First considerations in this regard were already made in the early 20th century with the 
notions that bone-marrow stimulation would lead to blood inflow and clot formation at the lesion 
site to initiate a natural repair process and that osteochondral tissue could be used as grafting 
material for damaged cartilage areas.[272,273] This eventually lead to the development of Pridie drilling 
in 1959 as the first clinically applied cartilage regeneration technique which was a progenitor of the 
nowadays widely used microfracturing technique and osteochondral autografting in 1985 with its 
advanced derivative called mosaicplasty (since 1992).[274–276] However, the occurrence of 
fibrocartilage formation with only short-term regenerative outcomes and the general risks for 
donor-site morbidity are frequent problems after the application of microfracture and mosaicplasty 
treatments, respectively. To tackle these issues, autologous chondrocyte transplantation (ACI) was 
invented by Brittberg et al. in 1994 and continuously developed in the following years resulting in 
a recent EMA approval of the third generation ACI.[277,278] Despite having several benefits like an 
improved hyaline-like cartilage deposition and reduced donor-site morbidity risks, long-term 
evaluations revealed no significant differences in the outcomes with ACI compared to the other 
repair approaches, particularly in case of elderly patients. Besides the catabolic influences from the 
degenerative environment of the highly inflamed joint in late-stage OA, this lack of a sustainable 
regeneration could be attributed to an impaired capability of the chondrocytes from older people 
to synthesize sufficient amounts of cartilaginous ECM and the general inability of the clinically 
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applied methods to reconstitute the hierarchical architecture of the native articular cartilage which 
is considered as a relevant characteristic for its unique biomechanical properties. In addition, 
autologous chondrocytes are low in abundance and have a limited proliferation potential combined 
with a tendency to lose their chondrogenic phenotype in expansion culture. Therefore, allogeneic 
chondrocytes and especially multi- and pluripotent stem cells became the focus of cartilage 
regenerative medicine in the recent years with the intend to use various tissue engineering 
techniques for studying chondrogenesis and fabricating artificial cartilage constructs in vitro. Among 
these various cell types, MSCs are considered as highly promising due to their chondrogenic 
potential, high abundance, simple expansion culture and the general benefits of their 
immunomodulatory properties. However, the in vitro and in vivo application of cell suspensions and 
high density MSC pellet cultures resulted in low cell viabilities and terminal differentiation issues 
with the expression of hypertrophic and fibrocartilage markers, respectively. To address these 
problems, different hydrogel-based scaffolding materials composed of natural and synthetic 
polymers that have been modified with biofunctional cues were developed in the recent years to 
provide embedded cells with an artificial matrix support in order to direct the chondrogenic 
differentiation and ECM production. In parallel, the advancement in fabrication technologies gave 
rise to a variety of additive manufacturing methods including electrospinning and 3D bioprinting 
which were increasingly implemented into cartilage tissue engineering approaches over the last 
decade with the aim to fabricate structured and reproducible constructs with controllable tissue 
organization and the possibility to apply hybrid material deposition methods.[9] Despite significant 
progress in these research fields, biofunctional articular cartilage-like tissues using stem cells could 
not have been produced yet, particularly due to an incomplete understanding of important cell-
matrix and cell-cell interactions under the influence of different biochemical cues for a successful 
chondrogenesis. Hence, there is still a strong demand for suitable bioinks and scaffolding materials 
to study the underlying principles of in vitro cartilage formation and to use these insights in 
combination with appropriate biofabrication techniques for sophisticated cartilage tissue 
engineering approaches. 
 
5.1 Summary and conclusion of the thesis 
In this work, a dual component starPEG-heparin hydrogel system was investigated as cell-
instructive scaffolding material for the chondrogenic differentiation of hMSCs in an in vitro 3D 
culture model. Being a highly sulfated GAG, heparin is the major bioactive hydrogel component 
with the ability to readily bind and stabilize a variety of growth factors including TGF-ß1, FGF-2 
and PDGF-BB. This property has been already utilized in chondrocyte-based cartilage regeneration 
approaches where heparin and heparan sulfate-based hydrogels proved to be notedly beneficial for 
a successful chondrogenesis in vitro and in vivo.[259,261] The hydrogel was additionally modified with 
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MMP-sensitive peptide linkers and RGD cell adhesion-mediating peptide motifs to provide a 
biomimetic microenvironment for the embedded cells. It is known that MMP degradability and 
RGD functionalization support the chondrogenic differentiation of MSCs.[279–282] However, the 
application of a multifunctional hydrogel scaffold that combines crucial properties of native ECMs 
such as sulfated GAG-mediated binding of signaling molecules, enzymatic degradability and the 
presentation of intrinsic cell adhesion sites in one system to promote hMSC-based chondrogenesis 
has not been reported yet. Furthermore, a custom-designed inkjet printing method using a 
piezoelectric dual pipette setup was applied to print structured cell-laden hydrogel scaffolds as 
potential strategy to mimic the zonal architecture of articular cartilage in engineered constructs. 
Among a variety of approaches, 3D bioprinting is generally seen as promising tool in this 
endeavor.[11] 
In order to enable the fabrication of printed hydrogel constructs, the initial step was the 
development of appropriate protocols for the inkjet printer “Nanoplotter 2”. Central printing 
parameters including the spot distance, number of hydrogel droplets per spot, the applied voltage 
and the polymer content of the gel precursor solutions were varied and adjusted which resulted in 
the successful printing of horizontally and vertically structured hydrogel scaffolds with controllable 
size and high reproducibility. The subsequent introduction of various cell types to the printing 
process by incorporation into the polymer solutions proved to have no adverse effects on the post-
printing viability in the cell-laden hydrogel scaffolds. In addition, the plotted cells were highly 
homogeneously distributed which is an important basis for a uniform tissue formation. A general 
drawback of many 3D bioprinting methods is the necessity to apply UV irradiation in order to 
solidify the bioink and to improve its mechanical properties which adds the risk of having 
potentially harmful side effects like DNA damage and an impaired cell survival and functionality. 
Due to the cytocompatible Michael type addition of the maleimide- and thiol-functionalized 
polymers as gel-forming crosslinking reaction of the heparin-based hydrogel platform, such post-
processing treatments were not needed to be applied while a high shape fidelity of the produced 
constructs was maintained by a fast polymerization time.  
An advantage of inkjet-based printing techniques is their capability of a layer-by-layer material 
deposition with high precision.[283] This property can be useful for the reconstitution of organs and 
tissues with a layered structure like skin and cartilage. The hierarchical architecture of articular 
cartilage is composed of 4 distinct zones with different ECM compositions, cell densities and layer 
thicknesses in the range from 100 µm to 1.2 mm in case of the superficial and middle zone, 
respectively.[284,285] To demonstrate the general feasibility of the developed printing protocols to 
fabricate hydrogel scaffolds with similar structural organization and dimension, layered, hMSC-
laden hydrogels with different cell densities and variable layer deposition patterns of starPEG-
heparin and pure PEG gels were successfully printed. Despite having a lower resolution than the 
cell-free versions, the achievable smallest thickness of a cell-containing layer was about 100 µm and 
therefore well in the range of the superficial zone of articular cartilage. In addition, these findings 
were used to print multilayered hydrogel scaffolds containing 6O,N-desulfated heparin for a 
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PDGF-BB-induced hMSC migration assay. The constructs were designed to have a zonal 
architecture composed of distinct cell- and growth factor-containing gel layers which allowed the 
formation of a sustainable, chemotactic PDGF-BB gradient that successfully triggered the cell 
migration over a culture period of 4 weeks. This experiment was used as a proof-of-concept 
approach that verified the functional integrity of the printed cells and the long-term stability of the 
fabricated, layered architectures. 
Next, the focus was on the chondrogenic differentiation of MSCs being the main objective of this 
thesis. Besides the biomolecular stimulation by different chondroinductive agents like TGF-ß1 or 
dexamethasone, the MSC chondrogenesis is correlated with the extend of cell-cell contacts that are 
necessary to activate certain intracellular signaling pathways which stimulate the expression of 
cartilage-related genes.[286,287] This mechanism can be found in the embryogenic cartilage formation 
process where the pre-cartilaginous condensation of mesenchymal chondroprogenitor cells is the 
initial step that onsets the chondrogenic differentiation. In order to achieve a sufficient amount of 
cell-cell contacts, high cell density or pellet cultures are required. Therefore, different hMSC 
concentrations were tested to determine the maximally printable cell density. As upper limit, a 
concentration of around 8 million cells per ml was found. However, a density of 5-6 million was 
considered as practical due to the high abundance of clocking issues at greater concentrations 
caused by an elevated tendency for cell aggregate formation. While being on a par with other inkjet 
bioprinting techniques in this regard, it has been reported that with an increasing cell concentration 
to around 20-30 million cells per ml in scaffold-based chondrogenesis approaches the production 
of cartilage-specific ECM components was significantly increased while even higher cell density 
levels only had minor improvements on the overall performance.[288–290]  
Based on these findings, the 3D cell proliferation of hMSC-laden starPEG-heparin hydrogels was 
investigated as a compensative measure for the limited printable cell density and to enhance the 
potential of printed hydrogels. Different concentrations of FGF-2 being a potent stimulator of 
MSC proliferation with chondroenhancing properties in combination with various FBS contents 
in medium were tested on fully MMP-degradable hydrogels with low, middle and high crosslinking 
degrees. While having a high cell viability, an increase in 3D cell density was not achieved under all 
conditions after 14 days in culture. The most pronounced cell responses were observed in soft 
starPEG-heparin hydrogels which was indicated by cell spreading and a strong 2D cell proliferation 
on the gel surface when high FGF-2 doses were applied.  
Despite this lack of a proliferative cell density increase, cell-laden hydrogels were printed for the 
chondrogenic differentiation which was induced by TGF-ß1- and dexamethasone-supplemented 
medium for a culture period of 6 weeks. In addition, different hydrogel crosslinking degrees were 
used to produce scaffolds with varied gel stiffnesses. This was based on the principle that besides 
the biochemical composition of the cellular microenvironment the mechanical properties of the 
surrounding matrix have an equally important influence on the differentiation of stem cells.[291] The 
analysis of the biofabricated hydrogel constructs with immunohistochemistry revealed positive 
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staining for collagen type II as the most important cartilage-related marker, little staining for the 
fibrocartilage marker collagen type I and no staining for collagen type X being an indicator for 
cartilage hypertrophy. This observed lack of collagen type X is considered as a particularly 
important and positive characteristic of the engineered constructs since hypertrophic development 
is a commonly known problem of MSC-based chondrogenic differentiation approaches bearing 
the risk of an onsetting endochondral ossification process which would lead to undesired bone 
formation. However, when the printed constructs were compared to casted gel controls, the 
staining intensity was significantly lower in case of the printed versions regardless of the 
crosslinking degree. These observations were made for all tested donors. The lower applied cell 
density was considered as the primary reason for the relatively weaker performance of the 
bioprinted gels in this regard. 
The results obtained for printed constructs and the lack of options to enhance the outcome with 
the available technology in order to match the matrix production in casted hydrogels led to the 
decision to discontinue the application of dual-pipette inkjet printing as biofabrication tool for in 
vitro cartilage formation and to switch the focus on the chondrogenic differentiation of hMSCs in 
casted starPEG-heparin hydrogels.  
The influence of the mechanical properties of casted constructs on the chondrogenesis was 
characterized by a significantly higher staining intensity for collagen type I in gels with a medium 
crosslinking degree compared to high crosslinking gels while the collagen type II staining was 
similar for all gel stiffness levels. This behavior which is generally expected to appear in stiff cell 
environments and is interpreted as marker for fibrocartilage formation and possible indicator for a 
potential osteogenic lineage commitment has also been reported in chondroitin sulfate-containing 
gels where a significantly higher collagen type I deposition was observed in soft hydrogels 
compared to stiffer gel controls.[245] Therefore, starPEG-heparin hydrogels with the highest 
crosslinking density and initial stiffness were chosen as the preferable condition for further 
investigations.  
A common issue of primary stem cell-based tissue engineering approaches is the high donor-to-
donor variation of the outcomes.[292–294] To test the donor-independent chondrogenic potential of 
heparin-based hydrogels, hMSCs from 3 different donors were used in starPEG-heparin gels with 
the aforementioned optimized composition and evaluated against the performance of scaffold-free 
micromass cultures which are generally used to study MSC chondrogenesis in vitro.[247] A successful 
chondrogenic differentiation was demonstrated by the homogeneous deposition of collagen type 
II across the whole hydrogel visualized by immunostaining for all tested donors while collagen type 
I showed a relatively low staining intensity and collagen type X was not detected at all. In addition, 
these results were comparable to the intensity and matrix composition of the micromass cultures 
and proved the chondrosupportive qualities of MMP-degradable, RGD-functionalized starPEG-
heparin hydrogels. When the temporal development of the differentiation was investigated, an 
almost linear trend of the ECM production was observed as determined by the total collagen 
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content which started to rise already after 7 days in culture while first positive staining for collagen 
type II appeared after 14 days. However, the gel stiffness of the engineered constructs measured 
by AFM nanoindentation did not increase over the whole culture period of 6 weeks. It is well 
known that, besides the high sulfated GAG content producing a strong osmotic pressure to 
withstand tissue deformation, the biomechanical properties of cartilage readily depend on the 
density and organization of its highly crosslinked collagen network which accounts for about 15-
20% of the total mass.[20,295] In comparison, the total collagen content in relation to the wet weight 
of hMSC-laden starPEG-heparin hydrogels reached only a level of about 0.5% after 6 weeks. 
Though being in the range of what other MSC-based cartilage tissue engineering approaches have 
reported, this was still almost 2 orders of magnitude below the values of the native tissue and was 
regarded as a major reason for the lack of a gel stiffness increase. Hence, it was decided to find 
conditions that would stimulate the overall cartilaginous matrix production in hMSC-laden 
starPEG-heparin hydrogels without upregulating the expression of fibrocartilage and hypertrophy 
markers. 
In order to determine suitable methods, the strategic course of action was divided into 2 parts: (1) 
the application of selected external stimuli and (2) the alteration of intrinsic hydrogel properties. 
As external stimuli, a multiple growth factor supply approach and macromolecular crowding from 
the medium were chosen. These strategies were based on the idea that by providing important 
properties of developing and adult articular cartilage, the cells would increase their chondrogenic 
commitment and produce more matrix. This has been demonstrated by the selected triple growth 
factor approach that used a combination of TGF-ß1, BMP-7 and IGF-1 being important regulators 
of the in vivo chondrogenesis and cartilage homeostasis to significantly enhance the ECM 
production of MSCs in PEG-based hydrogels.[111] Additionally, macromolecular crowding as 
second approach was expected to increase the effective concentration of biochemical cues and 
ECM precursors to enhance the density of the deposited matrix as it has been shown in 2D 
cultures.[256] In contrast to the reported effects of these measures, their application with hMSC-
laden starPEG-heparin hydrogels did not prove to have any beneficial influences on the overall 
matrix production. Neither the single supply of BMP-7 to the TGF-ß1-containing medium, the 
IGF-1 hydrogel preloading nor the combined application of all three growth factors at relatively 
high concentration levels resulted in observable differences in the extend of cartilaginous ECM 
deposition when compared to the control condition as indicated by similar immunostaining 
outcomes and total collagen contents. Furthermore, macromolecular crowding showed to even 
have a negative influence on the chondrogenesis which culminated in the complete inhibition at 
the highest applied crowder concentration. 
For the second part of the outlined strategy, the modular nature of the starPEG-heparin hydrogel 
system provided the possibility to alter selected gel parameters independently from each other to 
isolate their effect on the cellular processes. Since the impact of the hydrogel stiffness was already 
investigated and the RGD functionalization was proved to be generally supportive, the focus was 
on the MMP degradability and the heparin content as tunable properties to potentially enhance the 
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chondrogenesis and to study their influence on the differentiation. The incremental reduction of 
the MMP degradability from the standard 75% level to the non-degradable composition showed 
donor-dependent responses indicated by a significantly reduced total collagen content and weaker 
collagen type II staining at decreased PEG-MMP contents for one donor and comparable 
outcomes for another donor regardless of the degradability level. However, the hydrogel stiffness 
did not increase for all tested conditions and donors after the full culture period. These findings 
therefore indicated that the variation of the MMP degradability was not a suitable measure to 
enhance the biomechanical properties of the fabricated constructs. In contrast, the systematic 
lowering of the heparin content while maintaining a constant initial gel stiffness proved to be highly 
beneficial for the chondrogenesis. For all 3 tested donors, the biochemical and physical properties 
of the engineered constructs improved considerably in low and heparin-free gels compared to the 
standard hydrogel composition (1.5 mM heparin concentration). This was indicated by a significant 
increase in the total deposited collagen and a higher hydrogel stiffness for a < 10% heparin content 
(< 0.15 mM) and in pure PEG gels while having no adverse effects on the collagen matrix 
composition as demonstrated by similar staining intensities for collagen type II and I and the 
absence of collagen type X. The rise in stiffness seemed to be directly correlated with the content 
of the produced ECM. Additionally, a toluidine blue staining revealed a strong increase in deposited 
sulfated GAG-rich proteoglycans in low heparin-containing and pure PEG gels which is another 
indicator of a successful chondrogenic differentiation. Furthermore, the heparin concentration had 
an influence on the morphology of the embedded cells which showed a more elongated, 
fibroblastic shape compared to a spherical appearance at low and normal heparin contents, 
respectively. In addition, these effects were also observed in a growth factor preloading-only 
experiment with graded starPEG-heparin hydrogels where different TGF-ß1 concentrations were 
added to the cell-laden polymer solutions with various heparin contents prior to the gelation while 
the resulting hydrogels were cultivated in TGF-ß1-free chondroinductive medium. With the intent 
to test the growth factor administration from graded heparin-based hydrogels and pure PEG gel 
controls over extended periods of time without external TGF-ß1 supply in order to mimic a 
possible condition of hydrogel implants in a cartilage defect in vivo, the results demonstrated a better 
performance of pure PEG gels compared to heparin-containing hydrogels. While there was a 
proportional correlation between the TGF-ß1 preloading concentration and the deposited ECM 
observable for all hydrogel compositions, heparin-free gels displayed significantly higher total 
collagen contents and stronger collagen type II staining at any given preloading compared to even 
low heparin-containing hydrogels. Furthermore, the PEG gels were disproportionally stiffer 
despite comparable total collagen contents in heparin-based hydrogels with a higher growth factor 
preloading which was in contrast to the direct correlation of stiffness and deposited matrix content 
observed when TGF-ß1 was supplied continuously via medium.  
Based on these outcomes, the heparin concentration was considered as the most important 
hydrogel parameter to regulate the chondrogenic differentiation of hydrogel embedded hMSCs and 
its reduction the key measure to enhance the cartilaginous ECM production and the mechanical 
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properties of the resulting engineered constructs. A possible explanation for this impairing effect 
of higher heparin contents might be a strong sequestration of TGF-ß1 and other cell-secreted 
soluble factors by the highly sulfated hydrogel environment resulting in a low growth factor 
availability and an accordingly affected cell-cell communication. Furthermore, the conformation of 
the deposited ECM and collagen fibril formation could have been influenced by the heparin 
building blocks of the hydrogel.[270,271,296] However, these hypotheses would not explain the 
successful application of heparin-containing hydrogels in chondrocyte-based approaches which 
also rely on the accessibility of soluble cues and an unconstrained matrix build-up.[259,261] 
Interestingly, when the sulfate content in the applied standard starPEG-heparin hydrogel is 
compared with articular cartilage which has a high concentration of the chondroitin and keratan 
sulfate-rich aggrecan proteoglycan, a comparable sulfate group density in the range of 100 mM can 
be found in both matrices (for the calculation, see appendix). Therefore, it can be hypothesized 
that highly negatively charged cellular microenvironments might have a different effect whether 
MSCs or chondrocytes are used as cell source for cartilage tissue engineering. In this regard, one 
can argue that MSCs synthesize their own sulfated GAG-rich ECM along the process of the 
chondrogenic differentiation while during the induction period a different cellular 
microenvironment is required. This argument would also be in accordance with the native 
embryonic chondrogenesis where mesenchymal chondroprogenitor cells produce a collagen type 
I-enriched matrix during the initial condensation phase while the deposition of collagen type II and 
sulfated GAG-containing proteoglycans is increased at later maturation stages when the progenitor 
cells have already differentiated into actively synthesizing chondroblasts.[42] 
Finally, the presented results delivered an important insight into the influential aspects of crucial 
cell-matrix interactions and a promising basis for the further investigation of the underlying 














The work that is presented in this thesis had the aim to deliver new insights into the combined 
application and development of a new scaffolding material and an innovative, custom-designed 
biofabrication method to promote hMSC-based chondrogenesis in vitro. Based on the objectives 
stated in the Introduction section, the following main conclusions can be derived from the 
presented results: 
• The applied dual-component inkjet bioprinting technique proved to be suitable for 
the successful printing of cell-free and -laden hydrogel scaffolds with controllable 
structure and high resolution; limitations were found for larger constructs and 
higher cell concentrations. 
 
• The custom-designed printing method turned out to be not a pursuable option for 
hMSC-based cartilage-like tissue formation due to a considerably weaker 
performance of printed scaffolds compared to casted starPEG-heparin hydrogels 
which in turn showed a successful chondrogenic differentiation. However, the 
engineered constructs still had inferior biochemical and mechanical properties 
when compared to native articular cartilage tissue. 
 
• The application of externally deployed stimulatory cues including a multiple 
growth factor supply strategy and macromolecular crowding on hMSC-laden 
starPEG-heparin hydrogels did not lead to enhanced biochemical and mechanical 
properties of the engineered constructs. However, the alteration of selected 
hydrogel parameters such as the crosslinking degree, the MMP degradability level 
and the heparin content revealed that heparin had the most important influence on 
the chondrogenic differentiation. The reduction of the heparin concentration was 
the only measure among the tested variables that significantly increased the 
cartilaginous ECM deposition and the resulting hydrogel stiffness. The underlying 
mechanism of this effect remained elusive and should be a central part in further 
investigations. 
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5.2 Future perspectives  
The questions that were answered with this work gave rise to a wide range of new issues to be 
addressed. Several options and tools to advance the scope of the experimental setting offer the 
possibility to apply strategies in order to tackle these problems and to get more insights into new 
ways for cartilage repair and OA treatments. 
Apparently, one aspect of future research with the starPEG-heparin hydrogel platform should be 
the understanding of the influential effects of heparin on the MSC chondrogenic differentiation. It 
must be examined whether the obtained results are based on a restricted growth factor availability 
or a different, so far unknown mechanism, and why chondrocytes seem to respond differently in 
a heparin-based environment. A potential experimental setup could apply a “tea bag”-like approach 
using well plate inserts to separate a cell-containing, TGF-ß1 preloaded heparin-free hydrogel 
scaffold from a heparin-containing gel used for directed growth factor sequestration and a heparin-
free, non-binding control to test the availability hypothesis. Additionally, a multiplex assay could 
be utilized to get a qualitative and quantitative analysis of important cell-secreted soluble factors 
from cell-laden hydrogels with graded heparin contents. 
In order to extend the utility of the bioprinting technique, the application of microextrusion could 
be taken into consideration. Despite a potentially lower printing resolution, this would solve the 
problem of the limited cell concentration and could increase the scale of printable constructs while 
maintaining a reasonable fabrication time. For this, a highly viscous bioink with a different 
crosslinking scheme would need to be developed based on the starPEG-heparin hydrogel system. 
A potential bioink could be composed of norbornene-modified heparin and starPEG that would 
be mixed with thiolated PEG polymers and the cells without initiating the in-situ hydrogel formation 
while the addition of hyaluronan or alginate would add the necessary viscosity to maintain the 
shape stability of the extruded, pre-crosslinked hydrogel scaffold. The gelation would be performed 
after the printing with a visible light-induced photopolymerization. Furthermore, the combined use 
of inkjet and microextrusion printing could also be a viable option to get the best from both worlds. 
An important aspect to be investigated would be the application of multiple growth factor-
containing cocktails for hydrogels with a reduced heparin content. Even though the tested TGF-
ß1/BMP-7/IGF-1 approach did not yield any beneficial effects in starPEG-heparin hydrogels, 
there could be significant potential at lower heparin concentrations. In order to find the appropriate 
parameters concerning composition, presentation and duration of the applied cocktails, a 
combinatorial methodology linked to a design of experiment analysis would be a promising 
approach to be pursued. 
Another issue that may be of interest would be the creation of osteochondral constructs in vitro. In 
this thesis, the hMSC-based chondrogenesis was examined only in free-swimming hydrogels 
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cultured in chondroinductive medium. However, the combined application of a chondrogenic 
hydrogel top layer attached to a subchondral bone-mimicking bottom layer containing 
osteogenically committed MSCs which would be embedded in a porous environment like a 
bioactive cryogel scaffold would offer a model to study the important interactions of cartilage and 
bone tissue and could be a potential strategy to replicate the elusive bone-cartilage transition zone. 
Besides the utilization and development of various biochemical and structural cues, different 
external stimuli such as mechanical loading and hypoxia would be additional measures that have 
been demonstrated to improve the biochemical and physical properties of engineered cartilage-like 
constructs.[115,297,298] Therefore, a suitable multifunctional bioreactor could be a versatile tool in this 
endeavor and would push the relevance of the in vitro -based approaches closer to in vivo models.[126] 
Finally, the development of a realistic osteoarthritic in vitro model would help to test the engineered 
constructs under disease-related conditions. Ideally, this would demand the establishment of an 
artificial highly inflammatory environment which may be induced by the application of selected 
cytokines (such as IL-1ß, IL-6 and TNF-α) located in a biomimetic osteochondral defect model 
where the embedded cartilage-like constructs would be cultured under mechanical loading over 















Chapter 4.1 – PDGF-BB-induced hMSC migration in printed 
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Chapter 4.2 – Chondrogenesis in casted and printed hydrogels 
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Chapter 4.3 – Influence of the heparin content 
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Chapter 5.1 – Calculation of the sulfate group density in starPEG-
heparin hydrogels and articular cartilage 
 
StarPEG-heparin hydrogel Articular Cartilage 
Polymer solid content: 5% @ γ = 1.5 
 5 mg polymer per 100 mg gel 
 2.24 mg HM6 and 2.76 mg PEG 
M(HM6) = 15000 g/mol 
M(Heparin) = 14000 g/mol 
 2.1 mg heparin per 100 mg gel 
 150 nmol heparin per 100 mg gel 
 
Sulfate groups per disaccharide unit: 2.6 
Disaccharide units per heparin: 25 
 Sulfate groups per heparin: 65 
 Sulfate groups in mols: 
9.75 µmol per 100 mg gel 
 
Hydrogel density: 1 g/ml (95% water 
content) 
 
 Sulfate group concentration: 
97.5 mmol/l 
sGAG content (ug/mg dry weight):[300] 150 
Water content:[301] 70% (average) 
 sGAG content (ug/mg wet weight): 45 
 4.5 mg sGAG per 100 mg Cartilage 
The vast majority of sGAG is part of 
aggrecan![302,303] 
M(aggrecan)[304] = 2600 kg/mol (in this range) 
M(core protein)[305] = 300 kg/mol 
 M(sGAG) = 2300 kg/mol 
 1.96 nmol sGAG per 100 mg Cartilage 
 
sGAG is composed of about 100 chondroitin 
sulfate chains (CS) and 30 keratan sulfate 
chains (KS) per aggrecan.[305,306]  
M(CS) = 20000 g/mol 
M(CS disaccharide unit) = 458 g/mol 
Sulfate groups per disaccharide: 1 
 43.7 sulfate groups per CS 
M(KS) = 10000 g/mol 
M(KS disaccharide unit) = 471 g/mol 
Sulfate groups per disaccharide: 1 
 21.2 sulfate groups per KS 
 ≈5000 sulfate groups per sGAG 
 
 Sulfate groups in mols: 
9.81 µmol per 100 mg Cartilage 
 
Cartilage density:[307] 1.1 g/ml  
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